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1 Introduction 
1.1 The brain-specific protein p42IP4 
1.1.1 Structure (Gene, Protein) 
 
The 42 kDa protein p42IP4 , also named centaurin α1 (Venkateswarlu et al., 1999) and 
PIP3BP (Tanaka et al., 1997) belongs to the family of ADAPs, a subfamily of human 
ArfGAPs and has been recently renamed as ADAP1 for a consensus nomenclature (Kahn et 
al., 2008). It has been cloned from rat, bovine, pig and human brain (Hammonds-Odie et al., 
1996; Sedehizade et al., 2002; Stricker et al., 1997; Tanaka et al., 1999; Venkateswarlu and 
Cullen, 1999).  
The only other member of this subfamily is centaurin α2, a protein that is 58% 
identical and 75% homologous to p42IP4 (Hanck et al., 2004). Members of this protein family 
contain an ADP ribosylation factor-GTPase activating protein (Arf-GAP) domain, responsible 
for facilitating the hydrolysis of bound GTP in small GTPases and two pleckstrin homology 
(PH) domains.  
p42IP4 is located on chromosome 7p22.3 and contains 11 exons. Although the p42IP4-
homologue centaurin α2 is located on chromosome 17q11.2 close to the NF1 locus, the 
number of exons of both proteins is identical (Hanck et al., 2004). 
p42IP4 has two PH-domains, one N-terminal Arf-GAP domain, which includes a Zn2+-
finger and ankyrin repeats, similar to the human leucocyte ankyrin (Hammonds-Odie et al., 
1996; Stricker et al., 1999).  
Furthermore, p42IP4 can bind phosphatidylinositol (3,4,5)-trisphosphate (PIP3), 
phosphatidylinositol (3,4)-bisphosphate PtdIns(3,4)P2 (PIP2) and inositoltetrakisphosphate 
(IP4). 
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Fig. 1.1 Domain structure of p42IP4. 
The domain structure of the L-shaped protein p42IP4 is shown including the preferentially binding sites for the 
p42IP4 ligands PIP2, PIP3 and IP4. 
 
Recently the crystal structure of free and IP4-bound p42IP4 was solved (Tong et al., 
2010). p42IP4 is an L-shaped protein with three domains, which are linked by two short 
helices. Furthermore both PH-domains build a β-barrel with one end blocked by a C-terminal 
α-helix and the other site open for binding of phosphoinositides (Tong et al., 2010). 
Additionally, it was shown there that the N-terminal PH domain binds PIP3 and IP4, whereas 
the PH-domain close to the C-terminus is able to bind PIP3 as well as PIP2 and IP4, although 
the latter with slightly decreased affinity (see Fig. 1.1). 
1.1.2 Localization within the cell  
 The phosphatidylinositol 3-kinase (PI3K) catalyzes the production of the 
second messengers PIP2 and PIP3, which are ligands of p42IP4 and bind to the PH-domains of 
p42IP4 as described in 1.1.1.. The PI3K can be activated by different growth signals, for 
instance growth factors (Rodgers and Theibert, 2002). 
Binding of PIP3 to p42IP4 in vitro results in localization on the plasma membrane, 
whereas binding of the water soluble ligand IP4 is accompanied with a dissociation of p42IP4 
from the membrane into the cytosol (Stricker et al., 1999; Stricker et al., 2003). Moreover, 
using deletion mutants it was shown that the Zn2+-finger contains a nuclear localization signal 
which targets the protein to the nucleus (Sedehizade et al., 2002).  
In vivo investigations on the release of p42IP4 from membranes under the influence of 
IP4 confirmed the previously observed dissociation of p42IP4 from membranes in vitro. 
Introduction 
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Moreover, both PH-domains, as well as the Zn2+-finger are mandatory for the membrane 
localization of p42IP4 (Sedehizade et al., 2005). 
Recent investigations showed that p42IP4 is also localized in mitochondria and thereby 
participates in regulation of mitochondrial Ca2+ (Galvita et al., 2009). 
1.1.3 Distribution in tissues 
p42IP4 is mainly expressed in neuronal tissue, and widely distributed in the human 
brain (Sedehizade et al., 2002). Interestingly, a strong signal for p42IP4 not only in brain and 
spinal chord, but also in peripheral blood and a weak signal in kidney was obtained in 
Northern Blots (Hanck et al., 2004). 
In the human cortex, p42IP4 is expressed in pyramidal neurons in the ganglion cell 
layer. The subcellular distribution of p42IP4 in cortical neurons and in Purkinje cells of the 
cerebellum is comparable; p42IP4 is located inside the nucleus and in the cytoplasm 
(Sedehizade et al., 2002). A similar expression pattern has been found in rat brain (Kreutz et 
al., 1997a). p42IP4 was also detected in retinal neurons of different mammals and the 
expression was attenuated after optic nerve crush (Kreutz et al., 1997b).  
Moreover, p42IP4 seems to be developmentally regulated in rat brain (Aggensteiner 
and Reiser, 2003) and to be expressed in Alzheimer’s disease (AD) brains, where it 
colocalizes with plaques (Reiser and Bernstein, 2002; Reiser and Bernstein, 2004). 
Investigations on invertebrates suggest a role for p42IP4 in tissue repair and 
regeneration. The highly conserved protein homologue of p42IP4 in the sea cucumber 
(Holothuria glaberrima) has been shown to be upregulated after injury and the subsequent 
regeneration process. This animal was used as a model to further characterize the molecular 
events during intestinal regeneration after injury (Rojas-Cartagena et al., 2007). 
Additionally, it was shown that the p42IP4 homologue MjCent from the shrimp 
(Marsupeneaus japonicus), was upregulated during white spot syndrome virus (WSSV) 
infection, but notably decreased in virus-resistant shrimps. The upregulation of the p42IP4 
homologue was suggested to demonstrate a close relationship between MjCent and WSSV 
invasion and host defense of the shrimp, M. japonicus (Wang et al., 2009). 
 
1.1.4 Interaction partners and substrates 
Although the physiological role of p42IP4 is not yet clear, the interaction with other 
proteins indicates a role as a scaffold protein for various cellular processes. Among the 
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proteins, which interact with p42IP4 are all the members of the casein kinase I family (Dubois 
et al., 2001) (Dubois et al., 2002). Also nucleolin, which contributes to the regulation of the 
mRNA of the amyloid-precursor-proteins (Dubois et al., 2003), isoforms of the protein kinase 
C (PKC) (Dubois et al., 2002; Zemlickova et al., 2003), the kinesin motor protein KIF13B 
(Venkateswarlu et al., 2005), the protein RanBPM (Haase et al., 2008) and the 
metalloendopeptidase nardilysin (Stricker et al., 2006) interact with p42IP4. 
It was shown that p42IP4 associates with a highly conserved part of casein kinase Iα 
and it was discussed that p42IP4 thereby anchors the kinase on the plasma membrane, because 
the kinase itself lacks a lipid binding domain (Dubois et al., 2001) . The casein kinase Iα is 
ubiquitously expressed in many eukaryotes similar to other members of this family of 
serine/threonine kinases. Casein kinase isoforms phosphorylate some of their target proteins 
dependent on previous phosphorylation by other kinases few residues C-terminal to the casein 
kinase phosphorylation site (reviewed in (Gross and Anderson, 1998)). p42IP4 is not 
phosphorylated by casein kinase Iα, but a missing pre-phosphorylation by another kinase 
could not be excluded. Moreover, p42IP4 binds to the kinase domain but does not influence the 
activity of the kinase (Dubois et al., 2001). Additionally, a functional relationship between 
p42IP4 and casein kinase Iα was discussed as the casein kinase Iα diminishes the effects of a 
Gcs1 mutant, which is a yeast homologue of p42IP4 (Dubois et al., 2001). 
Gcs1 is an Arf GAP in yeast (S. Cerevisiae) with the highest homology to p42IP4. Gcs1 
is responsible for the organization of the actin cytoskeleton, by stimulating the polymerization 
of actin. Yeast, which contain mutants of Gcs1 have problems in distributing the actin to the 
daughter-cells during cytokinesis (Blader et al., 1999). Moreover, p42IP4 was demonstrated to 
complement the yeast Gcs1-mutant and therefore proposed to have a functional correlation 
with Gcs1 (Venkateswarlu et al., 1999).  
Another interaction partner of p42IP4 is nucleolin. Interaction of nucleolin with p42IP4 
takes place exclusively in the presence of RNA. Both proteins build a complex with RNA, 
and treatment with RNase prevents the interaction (Dubois et al., 2003). Moreover, nucleolin 
takes part in the regulation of the mRNA of the amyloid-precursor-protein (APP) (Zaidi and 
Malter, 1995). The interaction with nucleolin is quite interesting for neurodegenerative 
diseases as it has been shown that p42IP4 is highly expressed in human Alzheimer’s disease 
(AD) brains (Reiser and Bernstein, 2002). 
Furthermore, p42IP4 interacts with the protein kinase C (PKC) (Zemlickova et al., 
2003). PKCs are involved in the regulation of the cytoskeleton and they are important for cell 
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proliferation, differentiation and apoptosis. Lipid second messengers like PIP3 can regulate 
members of the PKC-family. p42IP4 binds to the cysteine rich domain C1 of PKC, which is 
abundant in all members of the PKC-family. Moreover, p42IP4 is phosphorylated by the PKC 
at the PH-domain close to the C-terminus and within the zinc-finger in the region of the 
putative Arf-GAP-region (Zemlickova et al., 2003). Interestingly, PKCs can activate α-
secretase indirectly through the MAP kinases ERK1/2 (Diaz-Rodriguez et al., 2002) but can 
also directly activate α-secretases TACE and ADAM10 (Skovronsky et al., 2000). 
As mentioned before, p42IP4 contains an Arf-GAP domain close to the N-terminus. 
Moreover, experiments could prove that p42IP4 can complement the mutant GCS1-KO yeast 
strain. An in vivo evidence for intrinsic Arf-GAP-activity of p42IP4 was given for the 
interaction with Arf6 (Venkateswarlu et al., 2004). Moreover, it was discovered that p42IP4 
can also interact with Arf1, Arf5 in vitro and colocalizes with Arf5 and Arf6 in vivo, but only 
little colocalization with Arf1 was observed in vivo (Thacker et al., 2004). 
Arf6, as a small GTPase, can be found in two states of activity within the cell: 
activated (Arf6GTP), when bound to GTP, or inactive (Arf6GDP), when bound to GDP. Arf6GDP 
is present in endosomes, whereas, Arf6GTP localizes at the plasma membrane (Donaldson, 
2003). To change the activation status, guanine-nucleotide exchange factors (GEFs) and 
GTPase-activating proteins (GAPs) are necessary. For activation, the GEFs catalyze the 
exchange of the bound GDP with GTP. For inactivation, GAPs are necessary, which activate 
the intrinsic GTPase-function of Arfs, which then leads to hydrolysis of the bound GTP to 
GDP and inorganic phosphate. 
It was reported that KIF13B negatively regulates the GAP activity of p42IP4 for Arf6 
in vivo (Venkateswarlu et al., 2005). p42IP4 interacts through its GAP domain with the stalk 
domain of the kinesin motor protein KIF13B, which was discussed to explain the inhibition of 
the Arf-GAP activity of p42IP4 (Kanamarlapudi, 2005). 
Arf6 plays a role in migration processes of epithelial cells. Polarized epithelial cells 
are tightly connected through adherens junctions. To allow cell migration a disassembly of the 
adherens junctions is necessary. Activation of Arf6 supports the destruction of the adherens 
junctions.  
Moreover, Arf6 has been implicated in G-protein-coupled receptor (GPCR) 
trafficking, including internalization of the GPCR (Hunzicker-Dunn et al., 2002). It was 
demonstrated that p42IP4 participates in the Arf6 modulated GPCR trafficking of the beta 
adrenergic receptor, by inhibition of its internalization (Lawrence et al., 2005). 
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Interestingly, p42IP4 does not require its Arf-GAP activity to regulate the actin 
cytoskeleton (Thacker et al., 2004). Nevertheless, an catalytically inactive Arf-GAP mutant of 
p42IP4 has been shown to diminish dendritic differentiation (Moore et al., 2007). 
Furthermore, using large scale genome functional profiling it was shown that p42IP4 is 
a putative modulator of the AP-1 promoter (Chanda et al., 2003). It was discussed there that 
p42IP4 might modulate an oncogene transformation of cells via the AP-1 signaling pathway 
which also includes changes in cell adhesion (Chanda et al., 2003). 
In another large scale screening for activators of the MAP kinase pathways, 
overexpressed p42IP4 was found to be an activator for the ERK-MAP kinase pathway (Harada 
et al., 2003). Further investigations revealed that after stimulation with EGF and activation of 
the PI3K, p42IP4 is recruited to the plasma membrane, where it subsequently activates Ras 
(Hayashi et al., 2006). It was discussed there that p42IP4 may therefore act as an adaptor 
protein, linking the PI3K signaling pathway with the MAP-Kinase-pathway. 
To get further insight into the function of p42IP4, our laboratory performed a yeast two-
hybrid screen with a human cDNA library from brain. Among several potential protein 
interaction partners, a new interaction between p42IP4 and RanBPM was found. RanBPM is a 
protein, which is involved in various different processes in the cell. Further investigations 
demonstrated that the p42IP4-ligand IP4 is a concentration-dependent and stereoselective 
inhibitor of the interaction between RanBPM and p42IP4 (Haase et al., 2008). Interestingly, 
investigations on RanBPM showed that it can interact with the low density lipoprotein 
receptor-related protein (LRP) and the amyloid precursor protein (APP) in the brain 
(Lakshmana et al., 2009). Additionally, overexpression of RanBPM results in an increased 
Aß-production via interaction with LRP and BACE1 (Lakshmana et al., 2009). 
Recent investigations from our laboratory could demonstrate that p42IP4 interacts with 
the 2',3'-Cyclic-nucleotide 3'-phosphodiesterase (CNP) and α-tubulin. p42IP4 also influences 
the opening of the mitochondrial permeability transition pore (PTP), and thereby participates 
in the mitochondrial Ca2+ metabolism (Galvita et al., 2009).  
Although all interactions mentioned above give an idea about the manifold processes in 
which p42IP4 might be involved, a clear physiological function of p42IP4 has yet to be 
established.  
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1.2 The metalloendopeptidase nardilysin (NRD) 
1.2.1 Structure (Gene, Protein) 
Nardilysin (NRD) is a 140 kDa metalloendopeptidase, which cleaves their substrates 
preferentially at the N-terminus of arginine doublets (therefore the acronym NRDc) but it can 
also cleave on dibasic amino acids (Chesneau et al., 1994) and on monobasic sites (Chow et 
al., 2003). The NRD gene is located on chromosome 1p32.3 and contains 31 exons.  
There are two alternatively spliced variants of NRD (NRD1 and NRD2) which exhibit 
similar biochemical and enzymatic properties but differ in their expression in tissues (Hospital 
et al., 2000) (Hospital et al., 1997).  
NRD has an inverted consensus-binding site for Zn2+, where the common motif 
HEXXH, which is present in most metallopeptidases (Hooper, 1994), is replaced by HXXEH. 
Enzymes like NRD, containing this inverted motif belong to the Inverzinkin/M16-family of 
metalloendopeptidases. The difference to other members of the M16- family is that NRD 
contains an insertion of acidic amino acids –glutamate and aspartate- N-terminal to its 
catalytic domain. This insertion was therefore named „Acidic Domain (AD)† or DAC. 
Depending on the species, the DAC differs in the number of amino acid residues. The 
DAC from rat (Rattus norvegicus) has 71 amino acids, while the human DAC is shorter and 
has only 53 amino acids. Comparison of the amino acid sequence from mouse (Mus 
Musculus) with the rat sequence shows almost identical amino acids (Csuhai et al., 1998; 
Pierotti et al., 1994).  
It was demonstrated that NRD can be inhibited by polyamines like putrescine, 
spermidine, and spermine (Csuhai et al., 1998). Further characterization of the binding of 
spermine to NRD revealed that it binds to the DAC, which is not part of the active site of the 
enzyme (Csuhai et al., 1999a). Studies with the DAC from rat, mouse and human alone, 
suggest that the DAC can work as a functional binding domain (Ma et al., 2001).  
A report using trypsin and protease V8 to study the effects of limited proteolysis on 
NRD, suggest that although the N-terminal region of NRD is not important for enzymatic 
activity, together with the C-terminal region it may be important for proper folding of the 
metalloendopeptidase (Ma et al., 2002).  
It was shown that the DAC is not necessary for the catalytic activity of NRD and that 
this domain is considered to be an appendix to the global structure of the enzyme, which is 
                                                 
†
 To avoid confusion with AD, the abbreviation commonly used for Alzheimer’s disease, the Acidic Domain is 
named DAC in this thesis, although it is common in published reports of NRD to use AD to describe the Acidic 
Domain. 
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able to influence the activity of the enzyme (Hospital et al., 2002). Moreover, it was 
demonstrated in the same work that removal of this domain results in a three fold decreased 
activity of the enzyme. It was discussed that the DAC may act as a regulator for activity and 
stability of NRD. The DAC it is the part of NRD that takes part in binding of HB-EGF, Ca2+ 
and polyamines, the latter cooperatively. 
1.2.2 Distribution in tissues 
Using Northern Blot it was shown that NRD is abundant in all examined tissues, 
especially in skeletal muscle, in heart and testis (Fumagalli et al., 1998), where the highest 
expression can be found in testis. Furthermore, the expression of NRD seems to be 
developmentally regulated. In early development of mouse (E 10.5) NRD is highly expressed 
in neuronal tissue, like the CNS and in cephalic and spinal ganglia (Fumagalli et al., 1998). 
After that time point, it is possible to detect NRD also in other tissues. 
Comparison between the expression levels of NRD in different tissues showed that it 
is highly expressed in the urogenital system, especially during spermatogenesis (Chesneau et 
al., 1996) but also during maturation of oocytes (Ma et al., 2005). 
Recent investigations could reveal that NRD is widely but unevenly expressed in the 
human brain (Bernstein et al., 2007). Moreover, it was shown in that work that NRD is 
differently expressed at certain developmental stages. In early development NRD is expressed 
in both neuronal and glial cells, whereas at later time points the expression remains 
exclusively in neurons. 
Most recent reports could show that a considerable amount of neurons co-express 
NRD together with the α-secretases ADAM10 and ADAM17 (Bernstein et al., 2009). 
Additionally, co-expression of NRD, ADAM10 and ADAM17 is reduced in AD or Down 
Syndrome brains. 
 
1.2.3 Localization within the cell 
Besides the mainly cytosolic localization, NRD resides in many cells and cell lines on 
the cell surface and seems not to enter the secretory pathway (Hospital et al., 2000). It can be 
released from the cell membrane, but how NRD is anchored and released from the cell 
membrane is still not known. It was speculated that these processes occur in interaction with a 
protein partner because NRD has neither a peptide signal for export nor a domain for 
anchoring at the membrane. Furthermore, it was discussed that NRD could be myristoylated 
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but this was not shown until now (Hospital et al., 2000). Moreover, it was reported that NRD 
is able to shuttle between the nucleus and the cytosol (Ma et al., 2004). 
1.2.4 Substrates and protein interaction partners of NRD 
Only a few in vitro substrates were known for NRD. NRD cleaves somatostatin-28, 
dynorphin A, α-neoendorphine and miniglucagon in vitro (Csuhai et al., 1995), (Chesneau et 
al., 1994), (Fontes et al., 2005) (Chow et al., 2000). Moreover, the protein neuregulin 1 
(NRG1) is a substrate for NRD. Most recent studies showed for the first time physiologically 
relevant substrates of NRD (Kessler et al., 2011). NRD is able to complement the proteasome 
activity, where it contributes to both the C-terminal and N-terminal generation of Cytotoxic T 
lymphocytes epitopes of the Epstein-Barr virus protein EBNA3C and an epitope from the 
melanoma protein MART-1 (Kessler et al., 2011). 
NRD has different protein interaction partners. These are HB-EGF, the tyrosyl-tRNA-
ligase, p42IP4, ADAM10 and ADAM17.  
HB-EGF was originally identified in the culture medium of cultivated macrophages. It 
is synthesized as a type I transmembrane protein and can be shed enzymatically. This leads to 
a release of a 14 – 20 kDa growth factor, which can act then as an chemoattractant for cell-
proliferation and migration for many cell types (reviewed in (Nishi and Klagsbrun, 2004)). 
Furthermore, NRD supports the building of a complex between the mitochondrial 
malate dehydrogenase and the citrate synthase (Chow et al., 2005). 
Investigations of the ectodomain-shedding of HB-EGF via activation of the TNF-α-
converting enzyme (TACE, also known as a disintegrin and metalloprotease 17 (ADAM17)) 
have shown that NRD is able to enhance the shedding of HB-EGF (Nishi et al., 2006). 
Interestingly, NRD itself does not cleave HB-EGF (Nishi et al., 2001). Downregulation of 
NRD expression by siRNA technique diminishes the HB-EGF-shedding. Therefore, it was 
discussed that NRD might have an important function in ectodomain-shedding of HB-EGF. 
Extracellular shedding of proteins is a posttranslational modification, which releases 
the extracellular domain of membrane-bound proteins through proteolysis. This happens to a 
variety of membrane proteins and is rapidly induced by activation of cells from their resting 
state. How this induction happens is still unclear.  
Moreover, NRD enhances the α-secretase activity of ADAM10 and ADAM17, which 
results in lowered Aß-levels, increased sAPPα levels and thereby promotes the non-
amyloidogenic pathway (Hiraoka et al., 2007). It was also demonstrated that NRD can 
enhance the ectodomain shedding of TNF-α via the activation of ADAMs (Hiraoka et al., 
2008) 
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A report on the regulation of a voltage-gated potassium channel in smooth muscle 
cells demonstrated that NRD is expressed in human myometrium. There NRD regulates the 
expression of the maxi-K channel isoform mK44 on the plasma membrane and the expression 
of mK44 in response to changes in intracellular Ca2+. Moreover, NRD colocalizes with 
mK44, and the expression of NRD decreases in late gestation, whereas an increase can be 
observed during labor (Korovkina et al., 2009). 
1.2.5 Functionality 
Besides recent reports on NRD to complement the proteasome activity, the function of 
NRD is not yet clear (Kessler et al., 2011). Homozygous knock out mice for NRD have 
impaired axonal maturation and hypomyelination (Ohno et al., 2009). Additionally, these 
mice have impaired motor activity and display cognitive deficits.  
It is known that through binding of HB-EGF the activity of NRD can be modulated 
and might therefore have a role in migration processes or in processes of wound healing. It 
was shown that NRD enhances the cell migration via HB-EGF and the EGF-receptor (Nishi et 
al., 2001). The fact that NRD, as a receptor for HB-EGF is expressed in brain in 
neuroproliferative zones like the subventricular zone (SVZ) but less expressed in the granular 
layer of the hippocampus further supports the idea that NRD participates in migrational 
processes (Nishi et al., 2001). 
Additionally, as described in 1.2.4, NRD seems to play an important role not only in 
shedding of transmembrane proteins like HB-EGF, but also in shedding of neuregulin 
(NRG1) (Ohno et al., 2009). NRG1 is a major regulator of myelination, which can be shed via 
β-secretase (BACE1) (Willem et al., 2006) and also TACE (Montero et al., 2000). 
A special feature of some members of the M16-family of metalloendopeptidases is their 
ability to act bifunctionally, that is as a protease and through a non-enzymatic behavior. One 
example is the mitochondrial processing peptidase (MPP), which is also a member of the M16 
family. MPP acts as peptidase on proteins which are encoded in the nucleus and removes their 
mitochondrial targeting sequences (Ito, 1999). On the other hand, MPP as a subunit of the 
cytochrom-c-oxidase is part of the respiratory chain in some organisms and has no enzymatic 
function. 
1.3 Role of proteases in Alzheimer’s disease  
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by extracellular 
neuritic plaques and intracellular neurofibrillary tangles (Alzheimer et al., 1995). 
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Neuronal plaques are caused by the abnormal cleavage of the amyloid precursor protein 
(APP) through the β-secretase (BACE1), whereas the “tangles” are composed of 
hyperphosphorylated tau – a microtubule-associated protein (reviewed in (Mattson, 2004)). 
APP is a type 1 transmembrane glycoprotein with a single-membrane spanning domain, 
a large extracellular N-terminal domain and a short C-terminal domain, located inside the 
cytosol (Kang et al., 1987).  
 
Fig. 1.2 Schematic representation of the proteolytic shedding of the amyloid precursor protein (APP) 
(modified from (Mattson, 2004)) 
APP is transmembrane protein with a large extracellular N-terminal domain (green, N-terminal parts of the 
orange tube) and a short C-terminal domain (indicated in light blue), which is located inside the cytosol. APP is 
shed by secretases and the emerging products lead to either the non-amyloidogenic (illustrated on the left site) or 
the amyloidogenic (right site) pathway. The arrows indicate different cleavage sites in APP for the secretases. It 
is believed that an equilibrium between both pathways exists (arrows in the lower part). Shedding by α-secretase 
releases sAPPα and leaves an 83 aa C-terminal fragment of APP (C83) in the membrane, which will be 
processed by γ-secretase to p3 and AICD (APP intracellular domain). Shedding by β-secretase leads to the 
release of sAPPβ and the 99 aa C-terminal fragment of APP (C99) remains in the membrane. Subsequent 
cleavage by γ-secretase produces the neurotoxic Aβ40/42 and the AICD. AICD, produced by the γ-secretase can 
translocate to the nucleus and influence transcription.  
 
APP can be processed at different cleavage sites (Fig. 1.2) by different secretases 
resulting in the neurotoxic Aβ40/42, through cleavage of BACE1 and subsequent γ-secretase 
(Haass, 2004), or in the neuroprotective sAPPα, produced by α-secretase (Selkoe and Schenk, 
2003).  
Although the identity of the α-secretase is not yet clear, several ADAMs (9, 10, 17) 
were shown to cleave APP at the α-secretase site (Asai et al., 2003). After α-secretase 
cleavage the remaining 83 amino acid C-teminal fragment of APP is further processed by the 
γ-secretase and leads to the release of p3 peptides.  
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Cleavage by BACE1 leads to the amyloidogenic pathway as it results in production of 
sAPPβ and subsequent cleavage by the γ-secretase releases the neurotoxic Aß-peptides which 
are parts of the neuronal plaques. It is believed that under non-pathological conditions an 
equilibrium between α- and β- secretase cleavage of APP exists. As mentioned before, the 
shedding of APP by α-secretases releases the neuroprotective sAPPα. Increased release of 
sAPPα also reduces the Aß-levels and is therefore called the non-amyloidogenic pathway 
(amyloid hypothesis reviewed in (Hardy and Selkoe, 2002)). 
The accumulation of Aß in the brain was proposed to be the primary influence in AD, 
followed by hyperphosphorylation of tau (reviewed in (Hardy and Selkoe, 2002)). 
Nevertheless, it is also discussed that the tau-pathology might be more important for the 
neurodegenerative development, because other dementias, like frontotemporal dementia are 
also linked to tau pathology (Spillantini et al., 1998), but lack amyloid plaques. 
1.4 Retinoic Acid 
Retinoic acid (RA) is a derivative of retinol (vitamin A), which has an important role 
not only in pattern formation during embryonal development but also in the adult brain 
(Niederreither and Dolle, 2008). Moreover, in neurodegenerative diseases like AD, the supply 
of RA is diminished in patients suffering from AD (Goodman, 2006; Goodman and Pardee, 
2003). Moreover, it was shown that an age-related decline of RA results in reduction of 
hippocampal function in memory processes (Mingaud et al., 2008). 
The precursor retinol enters the cell and is converted to retinal and finally to RA. RA 
binds to retinoic acid receptors (RAR and RXR) which then translocate to the nucleus and 
activate the transcription of target genes. RA receptors are ligand-activated nuclear 
transcription factors, which can bind to RA-responsive elements (RARE). 
RA regulates the expression of various target genes, which are involved in AD like 
BACE1, ADAM10, PS1 or APP. Most recent reports showed that all secretases involved in 
APP shedding are regulated by RA on gene and protein level (Koryakina et al., 2009). 
RA is often used to differentiate neuroblastoma cells (Pahlman et al., 1984). It was 
shown that NRD is upregulated in SK-N-BE cells after stimulation with RA (Draoui et al., 
1997). Furthermore, it was proposed in that paper that the NRD gene might contain RARE 
elements. Studies on the promoter of NRD revealed that the 5´upstream region lacks this 
proposed RARE sequence (Winter and Pierotti, 2000). 
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1.5 SH-SY5Y neuroblastoma cells 
SH-SY5Y cells are a catecholaminergic neuroblastoma cell line, which was derived as a 
third generation subclone of the cell line SK-N-SH (Biedler et al., 1973) (Biedler et al., 1978).  
Like many other neuroblastoma cell lines, SH-SY5Y can be differentiated into a 
neuronal-like cell type when exposed to low concentrations of RA and used as an in vitro 
model to study the properties of neurons (Pahlman et al., 1984). 
This cell line was shown to consist of two phenotypes with a majority of neuroblast-like 
cells. Additionally, upon stimulation with RA 25% of the cells grow extensions longer than 
50 µm and the non-neuronal phenotype will increase dramatically at the same time (Preis et 
al., 1988). The ratio of actin expression to total protein expression was significantly increased 
in cells differentiated with RA (Asada et al., 1994). Moreover, it was demonstrated that 
treatment of SH-SY5Y cells with RA upregulates the gene expression of APP (Beckman and 
Iverfeldt, 1997).  
Investigations on SH-SY5Y cells on cell renewal and commitment using 
electrophysiological and immunocytochemical approaches revealed that the parental SH-
SY5Y clone contains a pool of cells (S0 cells) which are able to renew and to differentiate to 
both smooth muscle (S1 and finally S2 cells) and neuronal cells (NS) (Biagiotti et al., 2006). 
Furthermore, the parental cells contain highly clonogenic cells (NN cells). Differentiation into 
the smooth muscle cells occurs with prolonged culture of the SH-SY5Y cells but only a 
simultaneous removal of the N type enables the final differentiation and leads also to the 
exhaustion of the culture (Biagiotti et al., 2006). 
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1.6 Aims for the thesis project 
The interaction between p42IP4 and NRD was discovered using a NRD -affinity-matrix 
(Chow et al., 2005). In this study, p42IP4 was identified via mass spectrometry as one of the 
proteins which were eluted from the NRD-affinity matrix (Chow et al., 2005). Investigations 
in our laboratory demonstrated that the DAC of NRD is sufficient for the interaction with 
p42IP4, can be regulated by ligands of both proteins (Stricker et al., 2006). 
1.6.1 Cloning of human NRD and purification of the active enzyme for in vitro 
experiments 
The first aim of this study is to clone the whole sequence of human NRD and to 
express it as an active enzyme. The purified, active enzyme should then be used to study 
functional aspects of the interaction with p42IP4, to clarify, whether p42IP4 can serve as a 
substrate for NRD. Further investigations should clarify whether the binding of p42IP4 to NRD 
has an impact on the activity of the enzyme. 
1.6.2 In vitro and in vivo experiments to investigate the interaction of p42IP4 and 
NRD  
It is known from the literature that p42IP4 and NRD are regulated during development, 
but it is unknown whether there is a connection between both proteins. Therefore, the 
expression of p42IP4 and NRD under developmental aspects should be studied in a suitable 
cell model system using RT-PCR and Western Blotting and confocal microscopy.  
Moreover, besides colocalization demonstrated by confocal microscopy, the 
interaction of p42IP4 and NRD has to be confirmed with biochemical methods. This helps to 
elucidate the relevance of their colocalization. For this purpose, pull down experiments and 
Far Western blots should be performed using recombinant p42IP4, recombinant NRD, and 
NRD-mutants. 
It has been published that NRD is able to enhance the α-secretase cleavage of APP and 
thereby provides evidence to be an anti-AD protein. p42IP4 is localized in AD plaques and 
interacts with RanBPM, a protein recently shown to enhance the cleavage of APP by BACE. 
Therefore, it has to be investigated, whether p42IP4 has an impact on the shedding of APP.  
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2 Materials and methods 
2.1 Materials 
2.1.1 Chemicals  
Gentamycin        Invitrogen 
Tetracycline  
Bluo-Gal  
Isopropylthio-β-galactoside  
Blasticidin S HCl 
Trypsin 
 
Ampicillin        Biochrom, Berlin, Germany 
Dulbecco’s Modified Eagle’s Medium (DMEM)  
DMEM + HAM’S F12 (1:1) 
Fetal calf serum (FCS) 
HBSS (w/o Ca2+ and Mg2+)  
Kanamycin sulphate  
Trypsin/EDTA  
Penicillin and Streptomycin  
 
Aprotinin        Biomol 
Leupeptin 
Pepstatin A 
Pefablock 
Bacto Agar  BD Bioscience (Clontech), 
Heidelberg, Germany 
Bacto Tryptone  
Bacto Yeast extract  
 
Bio-Rad protein assay dye reagent concentrate Bio-Rad Laboratories, München, 
Germany 
KCl        Roth, Karlsruhe, Germany 
Ethanol 
Guanidine-HCl 
Isopropanol 
MgCl2 
Na2HPO4*2H2O 
NaCl 
NaHCO3 
RNase 
Non-fat dry milk 
Rotiblock ® 
 
Complete Protease Inhibitor Cocktail Roche Diagnostic, Mannheim, 
Germany 
FuGENETM 6 transfection reagent 
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G418 Sulphate       Calbiochem, La Jolla, CA, USA 
ImmersolTM 518N (Immersion oil for microscopy) Carl Zeiss, Oberkochen, Germany 
 
KH2PO4        Merck, Darmstadt, Germany 
 
MATra solution       IBA, Göttingen, Germany 
 
PFA (paraformaldehyde)     Fluka Chemika, Sigma, Germany 
 
Protein A/G Agarose       Santa Cruz, Heidelberg, Germany 
Protein A-Sepharose      GE Healthcare 
Tween 20        SIGMA, Deisenhofen, Germany 
all-trans-Retinoic Acid  
Benzamidine 
β-mercaptoethanol 
DMSO  
TEMED  
Ponceau S 
2.1.2 Antibodies 
2.1.2.1 Primary Antibodies 
Beta-amyloid 6E10, Protein G-Purified, Innovative Diagnostik-Systeme, 
Hamburg 
Nardilysin N20 (polyclonal goat, affinity purified),  Santa Cruz Biotechnology 
β-tubulin mouse monoclonal anti-β-tubulin I antibody Sigma 
GAPDH mouse monoclonal anti GAPDH antibody  Millipore 
Synaptotagmin mouse monoclonal     Synaptic Systems 
Synapsin1, mouse monoclonal     Synaptic Systems 
GFP rabbit polyclonal anti-GFP antibody   Cell signaling technology 
Mab-117-2  mouse monoclonal antibody, U- Kunzelmann, Dissertation Tübingen, 1994 
Rai-1 rabbit polyclonal antibody ; (Reiser et al., 1995) 
Rai-2 rabbit polyclonal antibody ; (Reiser et al., 1995) 
GM130 mouse monoclonal anti-GM130   BD Transduction Laboratories 
EEA1 mouse monoclonal anti-EEA1   BD Transduction Laboratories 
Anti-XpressTM-mouse monoclonal antibody   Invitrogen 
His-Antibody mouse monoclonal    Qiagen 
2.1.2.2 Secondary Antibodies 
goat anti-mouse-HRP IgG+M    Dianova, Hamburg, Germany 
goat anti-rabbit-HRP IgG      Dianova, Hamburg, Germany 
mouse anti-goat-HRP IgG      Dianova, Hamburg, Germany 
Alexa Fluor 488 donkey anti-goat IgG    Molecular Probes 
Alexa Fluor 555 donkey anti-goat IgG    Molecular Probes 
Alexa Fluor 546 goat anti-rabbit IgG    Molecular Probes 
Alexa Fluor 555 goat anti-rabbit IgG    Molecular Probes 
Alexa Fluor 568 goat anti-rabbit IgG    Molecular Probes 
 
Materials and methods 
 25 
2.1.3 Oligonucleotides 
 
Unless otherwise indicated, all primers were purchased from MWG, Ebersberg, Germany 
 
primer Sequence 5´-> 3´ 
CBhNRDHXXAHup TGG CAC ACT TTT TG GCG CAC ATG GTA TTC AT 
CBhNRDHXXAHlo AT GAA TAC CAT GTG CGC CA AAA AGT GTG CCA 
CBhNRDC948Aup GCA CAT GGA AGAA CCT GCT TTT GAC TTC CTT CGA 
CBhNRDC948Alo TCG AAG GAA GTC AAA AGC AGG TTCT TCC ATG TGC 
CBhNRDnoDAC1up ACA GGA AAT ACA ACC GGT GAT GAA GAA GAA GA 
CBhNRDnoDAC1lo TC TTC TTC TTC ATC ACC GGT TGT ATT TCC TGT 
CBhNRDnoDAC2up TTG GAA GAA TTA ACC GGT AGA GCA GAA GCT 
CBhNRDnoDAC2lo AGC TTC TGC TCT ACC GGT TAA TTC TTC CAA 
CBhNRDcor1054up CTT TTT GGA GCA CAT GGT ATT CAT GGG TAG TTT G 
CBhNRDcor1054lo C AAA CTA CCC ATG AAT ACC ATG TGC TCC AAA AAG 
hNRD2c1up TAA GTC AAC TTA TTC AAA AAT GTC TTC AAC 
hNRD2c1lo GTT GAA GAC ATT TTT GAA TAA GTT GAC TTA 
hNRD2c2up CTG CTG GTC GAG ACA AGA AAT CTT TAT GGG GT 
hNRD2c2lo AC CCC ATA AAG ATT TCT TGT CTC GAC CAG CAG 
CBHsNRDFW GAT CGC GGC CGC CCC GGG ATG CTG AGG AGA GTC 
ACT GTT G 
CBHsNRDstopRV GAT CCT CGA GTT ATT TGA CTA TTT TAT GGT AG 
CBHsNRDnonstopRV GAT CCT CGA GAA GCT TTG CTT TGA CTA TTT TAT GGT 
AGG GG 
CBRnNRDFW GTG GAG GGT AAA ACA GGA AAT GCA 
CBRnNRDRV AGG CAT CAA ATC CAT TCT CAT CTG 
CBNOFW CCT GGG AAG CGG GAT GTC 
CBN1FW TGA ATC TGA GGA AGA GGG AC 
CBN3FW AAA ATG TCT TCA ACC CTG C 
CBN4FW GAA TAA TAT TGA TAC ACA TGC 
CBN5FW GTT ATG AAC ATT TTT ATG AGG 
CBN6FW GGT TGC CTG TGG TAT AAG 
CBN7FW GGA ATG TCA CAA GCA CAG 
CBN8FW CTG GAA TGA AGT GGT TAC ACA CAG C 
CBN2RV GCT GGG AGA CTT GAC GAT C 
CBN3RV CCA TCC TGC CAA ATG CTG AAC 
CBN4RV GCA TGT GTA TCA ATA TTA TTC 
CBN5RV GCA ACC TCA TAA AAA TGT TCA TAA C 
CBN6RV CTT ATA CCA CAG GCA ACC 
CBN7RV GAT TCT GTG CTT GTG ACA TTC C 
CBN8RV GCT GTG TAA CCA CTT CAT TCC AG 
CBN9RV TTC AGG CCA ACG TGA CTG CAG 
M13fw (Invitrogen) GTA AAA CGA CGC CCA G 
M13rv (Invitrogen) CAG GAA ACA GCT ATG AC 
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2.1.4 Plasmid Vectors 
pcDNA6/HisB (Version B)  Invitrogen, Karlsruhe, Germany 
pFastBacHT_C (Version C)  Invitrogen, Karlsruhe, Germany 
pBluescriptII KS   Fermentas Life sciences 
pEGFP-C1    BD Biosciences Clontech 
 
2.1.5 Enzymes and buffers 
Shrimp Alkaline Phosphatase Boehringer, Mannheim, Germany 
T4 DNA Ligase    Invitrogen 
T4 DNA Polymerase   Invitrogen 
Not I, XhoI, EcoRI, HindIII,  Fermentas Life sciences 
BamHI, PvuI&II, NsbI 
Y/Tango (10X), R(red), G(green) 
AgeI, NEB1    New England Biolabs, Beverly, MA, USA 
 
2.1.6 Kits 
QuickChange Site-directed Mutagenesis kit   Stratagene, LaJolla,CA,USA 
Accu Prime       Invitrogen, Karlsruhe, Germany 
Bac-to-Bac®HT Vector Kit     Invitrogen, Karlsruhe, Germany 
Max Efficiency®DH10BacTM Competent E.coli Reagents Invitrogen, Karlsruhe, Germany 
Cellfectin® Transfection Reagent     Invitrogen, Karlsruhe, Germany 
HiSpeed Plasmid Midi kit     Qiagen, Hilden, Germany 
MinElute Gel extraction kit     Qiagen, Hilden, Germany 
QIAquick PCR purification kit    Qiagen, Hilden, Germany 
Taq Master Mix kit      Qiagen, Hilden, Germany 
Omniscript Reverse Transcription kit   Qiagen, Hilden, Germany 
RNase-Free DNase Set     Qiagen, Hilden, Germany 
RNeasy Mini kit      Qiagen, Hilden, Germany 
hAmyloid β40 ELISA (HS) the GENETICS company, 
Schlieren, Switzerland) 
Supersignal West Pico kit     Pierce, Rockford, IL, USA 
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2.1.7 Cells and cell culture reagents 
2.1.7.1 Mammalian cell lines 
2.1.7.1.1 HEK 293 cells 
Human embryonal kidney cells were cultured in DMEM/Ham’s F-12 (1:1) 
supplemented with heat-inactivated 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin 
(Biochrom, Berlin, Germany) in a humified, 5% CO2, 37°C incubator. 
2.1.7.1.2 SH-SY5Y cells 
SH-SY5Y cells were cultured in DMEM supplemented with heat-inactivated 15% 
FCS and antibiotics mixture (penicillin, 100 U/ml and streptomycin, 0.1 mg/ml; Sigma) in a 
humified, 5% CO2, 37°C incubator. 
2.1.7.2 Insect cells 
2.1.7.2.1 Sf9 (Spodoptera frugiperda) – cells 
Sf9 cells were cultured with IPL-41 insect medium with L-amino acids (Gibco), 
supplemented with 10% heat-inactivated FCS (Biochrom), 2% (v/v) yeast extract (Sigma), 1% 
(v/v) lipid medium supplements (Sigma), 100 µg/ml gentamycin sulfate (Cell Concepts), and 2.5 
µg/ml amphotericine B (Cell Concepts) in at 27°C.  
2.1.7.3 Bacterial strains 
Strain Genotype Reference 
DH10BacTM F´mcrA(mrr-hsdRMS-
mcrBC) 80lacZM15 
lacX74 recA1 endA1 
araD139 (ara,leu)7697 galU 
galK -rpsL 
nupG/bMON14272/pMON7124 
(Luckow, 1993) 
DH5α F´/endA1, hsdR17 (rk-mk+), 
glnV44, thi-1, recA1, gyrA 
(Nalr), relA1, D(laclZYAargF) 
U169, deoR, 
(f80dlacD(lacZ)M15) 
 
 
 
XL1-Blue supE44, hsdR17, recA1, 
endA1, gyrA46, thi, relA1, lac, 
[F’ proAB, lacIq, Z_M15, 
Tn10(tetr) 
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2.1.8 Technical equipment 
 
Sorvall RC5CPlus Dupont Instruments, Hamburg, Germany 
BIOFUGE pico (Lab centrifuge) Heraeus, Hamburg, Germany 
AHT35 Centrifuge (midi) Hettich Zentrifugen 
T3 thermocycler Biometra, Göttingen, Germany 
Thermomixer comfort Eppendorf ,Wesseling-Berzdorf, Germany 
LABINCO LD-79 (Rotating wheel) LABINCO b.v., Breda (NL) 
Agitateur Top-Mix 1118 (vortex) Bioblock Scientific 
Ultraturrax , IKA T25 IKA, Staufen, Germany 
LSM510 laser scanning confocal 
microscope 
Carl Zeiss, Jena, Germany 
Microplate reader Molecular devices 
BioRad GelDoc XR (Gel documentation 
system) 
Gel electrophoresis system 
Semi-dry Transfer Cell 
Electrophoresis power supply 
GS-800 Calibrated Densitometer 
Bio-Rad Laboratories, München, Germany 
UV/visible Spectrophotometer Pharmacia Biotech 
Ultrasonic homogenizer  Bandelin electronic, Berlin, Germany 
Mighty Small II (for western blotting 
electrophoresis) 
Amersham Pharmacia Biotech, 
Buckinghamshire, UK 
Magnet plate IBA, Göttingen, Germany 
Gel-blotting-papers Schleicher & Schuell, Dassel, Germany 
HybondTM-C Extra, Nitrocellulose, 45 
Micron 
GE-Healthcare 
PD10 column  GE-Healthcare 
X Ray films FUJI Super RX  
GENiosPlus (Microplate Reader) Tecan, Crailsheim Germany 
HB2448 LaminAir (bench) Heraeus, Hamburg, Germany 
Biofuge A, 13 R, 3.2 RS (centrifuge) Heraeus, Hamburg, Germany 
  
 
2.2 Methods 
2.2.1 Methods in molecular biology 
2.2.1.1 Isolation of nucleic acids 
2.2.1.1.1 Isolation of RNA from animal cells 
Isolation of RNA was done using the Qiagen RNeasy Mini kit.  
1. Add 350 µl buffer RLT to cell pellet (freshly harvested or frozen pellet, thawed on ice 
beforehand) 
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2. add 350 µl 70% EtOH to lysate, mix by pipetting and apply solution to a RNeasy mini 
spin column 
3. centrifuge for 15 min at 10000 rpm 
4. add 350 µl buffer RW1 to column 
5. centrifuge for 15 min at 13000 rpm to wash column 
6. add 10 µl DNase and 70 µl buffer RDD onto column membrane, incubate for 15 min 
at RT 
7. add 350 µl buffer RW1 to column 
8. centrifuge for 1 min at 10000 rpm  
9. add 500 µl buffer RPE to column, centrifuge for 15 min at 10000 rpm 
10. add 500 µl buffer RPE to column, centrifuge for 2 min at 10000 rpm, to wash column 
11.  to dry the silica membrane centrifuge empty column 
12. put column into fresh tube, add 25 µl RNase-free H2O directly onto the membrane and 
incubate for 10 min at RT 
13. centrifuge for 1 min at 10000 rpm to elute RNA, put on ice 
14.  store RNA at – 80 °C 
 
2.2.1.1.2 Isolation of plasmid DNA from bacteria (Mini-Preparation) 
 
Mini I-solution 50 mM Glucose 
25 mM Tris-HCl (pH 8.0) 
10 mM EDTA (pH 8.0) 
100 µg/ml RNase 
Mini II-solution 0.2 M NaOH 
1% SDS 
Mini III-solution 60 ml 5 M potassium acetate solution 
11.5 ml acetic acid 
28.8 ml H2O 
TE-buffer 10 mM Tris/HCl, pH 7.4 
1 mM EDTA, pH 8.0 
 
Isolation of plasmid DNA from bacteria: 
1. centrifuge overnight-culture for 5 min at 13000 g 
2. discard supernatant 
3. add 100 µl Mini I to resuspend the bacterial pellet 
4. add 200 µl Mini II, incubate for 10 min (alkaline lyses of bacterial cell wall) 
5. add 150 µl Mini III, incubate for 15 min on ice (denaturing proteins) 
6. centrifuge for 15 min at 13000 g 
7. transfer supernatant into a fresh Eppi 
8. add 300 µl isopropanol, invert tube and centrifuge for 5 min at 13000 g 
9. discard supernatant 
10. add 70% EtOH to precipitate DNA 
11. centrifuge at max speed for 10 min 
12. discard supernatant, dry pellet at 37°C 
13. dissolve pellet in 30 µl TE-buffer (optional: instead of TE add 30 µl TE-buffer 
containing RNase solution, incubate for 1 h at 37°C, to destroy any RNA (if present)) 
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2.2.1.1.3 Isolation of plasmid DNA from bacteria (Midi-preparation) 
Isolation of plasmid DNA in medium amount was done with the Qiagen HighSpeed 
Plasmid Midi Kit in steps as follows: 
1. inoculate culture, grow ON 
2. prechill buffer P3 on ice before starting 
3. centrifuge ON-culture at 6000 g for 5 min, discard supernatant 
4. add 6 ml buffer P1 (incl RNase), vortex to resuspend pellet 
5. add 6 ml buffer P2, mix and incubate for 5 min at RT 
6. add prechilled buffer P3, mix and put on QIAfilter Cartridge 
7. incubate for 10 min at RT 
8. during incubation time equilibrate the HiSpeed Midi Tip with 4 ml buffer QBT 
9. apply lysate to HiSpeed Midi Tip 
10. wash with 20 ml buffer QC 
11. eluate DNA with 5 ml buffer QF 
12. add 3.5 ml isopropanol to precipitate DNA, incubate for 5 min at RT and transfer 
precipitate onto a QIAprecipitator 
13.  wash precipitator with with 2 ml 70% EtOH and dry precipitator by pressing air 
through 
14. elute DNA from precipitator by adding 1 ml buffer TE 
15. store DNA at -20°C 
2.2.1.1.4 Transforming DH10BacTM E.coli 
Production of LB-plates for pFastBac-Transformations, containing Tetracycline, 
Kanamycin, Gentamycin, Bluo-Gal and IPTG (TetKaGeBlIP-plates) 
for 500 ml: 
5 g Tryptone 
2.5 g Yeast extract 
5 g NaCl 
adjust to pH 7.0 and add 7.5 g agar before autoclaving. 
After autoclaving cool liquid to ~ 55°C and add antibiotics, Bluo-Gal and IPTG using the 
following scheme:  
 
 Final concentration Stock solution for 500 ml 
Kanamycin 50 µg/ml 10 mg/ml 2.5 ml 
Gentamycin 7 µg/ml 10 mg/ml 0.350 ml 
Tetracyclin 10 µg/ml 10 mg/ml 0.5 ml 
Bluo-Gal 100 µg/ml 20 mg/ml 2.5 ml 
IPTG 40 µg/ml 200 mg/ml 0,1 ml 
(Dissolve 0.2 g Bluo-Gal in 10 ml DMSO)  
 
Pour LB-agar into 10cm plates, let them harden, invert them and store at 4°C, without 
exposure to light (Bluo-Gal and Tetracycline are light sensitive).  
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SOC media (250 ml): 
  Bacto tryptone   5 g 
Yeast extract    1.25 g 
NaCl     0.15 g 
KCl     0.125 g 
1M Glucose    5 ml (final 20 mM) 
1M MgCl2    2.5 ml (final 10 mM) 
1M MgSO4    2.5 ml (final 10 mM) 
 
Transformation procedure: 
1. thaw competent MAX Effiency® DH10BacTM cells on ice 
2. add 100 µl cells for each transformation into a 2ml Eppi  
3. add 1 ng (5 µl) cloned pFastBacHT-C-NRD-construct, mix gently  
4. incubate cells on ice for 30 min 
5. heat-shock: 45 sec at 42°C 
6. transfer tubes for chilling on ice for 2min  
7. add 900 µl SOC medium (RT)  
8. shake pFastBac-Transformations: 4 h, 225 rpm, at 37 °C  
9. pFastBac- Transformations: make 10 – fold dilutions (1:10, 1:100, 1:1000) with SOC 
– Media 
10. plate 100 µl of each dilution on a TetGeKaBlIP-LB-plate 
11. incubate for 48 h at 37°C 
12. pick 10 white colonies from each plate an replate them on a fresh TetGeKaBlIP-LB- 
plate 
13. incubate plates overnight at 37°C 
14. pick white colonies and inoculate them in LB, containing TetGeKa (10 / 7 / 50 µg/ml) 
15. incubate overnight in a shaking incubator at 37°C 
 
2.2.1.1.5 Isolation of recombinant bacmid DNA from DH10BacTM E.coli 
Isolation of bacmid DNA differs not much from isolation of plasmid DNA. All steps 
have to be done with more care, especially pipetting steps, as shearing forces may destroy the 
desired large sized recombinant bacmid DNA. 
Solution I  (15 mM Tris-HCl, pH 8.0, 10 mM, 100 µg/ml RNaseA) 
Solution II  (0.2 M NaOH, 1% SDS) 
3 M potassium acetate, pH 5.5 
1. Transfer 1.5 ml of cultures into an Eppi and centrifuge at 14000 g for 1 min 
2. Remove supernatant and gently resuspend pellet in 300 µl Solution I by careful 
pipetting up and down 
3. Add 300 µl Solution II, mix gently and incubate for 5 min at RT 
4. Slowly add 300 µl of 3 M potassium acetate, mix gently and place on ice for 10 min 
5. centrifuge for 10 min at 14000 g 
6. take fresh Eppi, add 800 µl isopropanol and transfer supernatant (step 5.) into Eppi 
7. invert tube several times, put on ice for 10 min 
8. centrifuge for 15 min at 14000 g (RT) 
9. remove supernatant, add 500 µl EtOH (70%) to wash pellet 
10. centrifuge for 5 min at 14000 g, RT, repeat 9. and 10 
11. remove supernatant, dry pellet and dissolve DNA pellet in 40 µl 1X TE-buffer 
12. store DNA at 4°C 
13. analyse recombinant bacmid DNA 
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2.2.1.1.6 Analysis of recombinant bacmid DNA 
Due to the larger size of recombinant bacmid DNA, PCR was performed using M13 
Forward and M13 reverse Primers or Primers specific for NRD (CBRnNRDFW, 
CBRnNRDRV), Taq-Polymerase Master Mix and a standard PCR protocol with annealing 
temperature of 62°C and 30 cycles. 
2.2.1.1.7 Isolation of DNA- fragments from agarose gels 
To elute DNA-fragments from agarose gels the MinElute Gel extraction kit (Qiagen) was 
used. The protocol was done as follows: 
1. Weight 2 ml Eppi 
2. cut DNA from gel (BioRad GelDoc XR, preparation mode ) and put gel into  the 2 ml 
Eppi 
3. weight again, calculate agarose weight 
4. add 3 fold gel-weight of buffer QG 
5. place Eppi on shaker for 10 min at 50 °C until the gel is dissolved 
6. add 1 gel volume isopropanol, invert Eppi and transfer mixture on a MinElute column 
7. centrifuge for 1 min at 13000 rpm 
8. add 500 µl buffer QG, centrifuge again for 1 min 
9. to wash column add 750 buffer PE, centrifuge for 1 min 
10. to dry column, centrifuge again and place column into fresh Eppi 
11. add 15 µl buffer EB (10 mM TrisHCl, pH 8.5) and incubate for 10 min at RT 
12. centrifuge for 2 min at 13000 rpm to elute DNA 
13. store DNA at -20°C 
  
2.2.1.2 Quantification of nucleic acids 
To quantify isolated DNA or RNA, dilute nucleic acids 1: 10 with water and measure 
the absorption in a quartz cuvette (5.00 mm thickness) by the UV absorption ratio 260 nm 
/280 nm using an Ultrospec 2000 UV/visible spectrophotometer (Pharmacia Biotech, 
Freiburg, Germany). Measurement at 260 nm shows the absorption of nucleic acid, at 280 nm 
the protein absorption. The ratio 260 nm /280 nm was used to determine the quality of the 
nucleic acid, as this ratio shows the contamination with proteins. A ratio of > 1.7 was 
considered to be acceptable. Additionally the quality of the nucleic acid was checked on a 
agarose / TBE gel, prestained with ethidium bromide (1.5 µl of stock solution 10 mg/ml). 
2.2.1.3 Precipitation of DNA for sequencing 
1. Take 20 µl DNA 
2. Add 2 µl Na-Acetate and 55 µl EtOH abs. 
3. Centrifuge 13000 rpm for 15 min 
4. Discard supernatant 
5. Wash with 250 µl 70% EtOH 
6. Centrifuge again for 15 min at 13000 rpm 
7. Remove supernatant, dry pellet 
8. Dissolve in 20 µl 10 mM TrisHCl and quantify the amount of precipitated DNA 
Sequencing was done by Seqlab GmbH, Göttingen, Germany 
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2.2.1.4 Production of cDNA 
cDNA was done with the Omniscript Reverse Transcription kit (Qiagen). For each 
RNA-sample the following Kit-components were added into a cDNA-Eppi: 
2 µl buffer 
2 µl dNTPs 
2 µl OligodT 
1 µl Reverse Transcriptase 
x µl RNA (x corresponds to the volume of 1 µg RNA) 
H2O ad 20 µl 
Synthesis was done using a T3 Thermocycler (Biometra®) and the following program: 
Lid temperature110°C 
37°C for 1h 
99°C for 5 min 
4°C until removal of samples 
2.2.1.5 Polymerase Chain Reaction (PCR) 
Amplification of DNA with PCR was done with the Taq-Polymerase Kit (Qiagen). 
The PCR reaction (25 µl) was set up in the following scheme: 
Add 1 µl specific cDNA, 2 µl specific Primer fw, 2 µl specific Primer rv, 12.5 µl Taq-
Polymerase-Mastermix and 7.5 µl H2O. PCR was performed in a T3 Thermocycler 
(Biometra®) using the following program: 
 
Standard PCR NRD: 
1. 94°C 3 min 
2. 94°C 30 sec 
3. 62°C 30 sec 
4. 72°C 1 min, 4.->2. 30 cycles 
5. 72°C 10 min 
6. 4.0°C, pause 
 
Standard PCR p42IP4: 
1. 96°C 2 min 
2. 95°C 30 sec 
3. 58°C 45 sec 
4. 72°C 3 min, 4.->2. 34 cycles 
5. 72°C 10 min 
6. 4.0°C, pause 
 
2.2.1.5.1 Non-quantitative PCR 
For first detection of expressed genes from different tissues or cell lines, PCR was 
performed using the cDNA and suitable primers for the gene. The PCR product was run on an 
agarose-gel and captured with a gel documentation system (BioRad GelDoc XR, Bio-Rad 
Laboratories). 
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2.2.1.5.2 PCR for molecular cloning 
Primers for cloning of the full coding sequence of NRD were designed according to 
sequences available in the Genbank (PubMed NM_002525.1) and included suitable restriction 
sites for subsequent cloning into the multiple cloning site (MCS) of pcDNA6/HisB and 
pFastBacHT_C. Moreover, primers with similar annealing temperature were used. The 
cloning PCR was done using the AccuPrime kit (Invitrogen). 
 
Cloning hNRD from HEK 293 cells 
5 µl cDNA 
5 µl Accu Prime Reaction mixture 
1 µl AccuPrime Polymerase 
2 µl CBHsNRDFW 
2 µl CBHsNRDstopRV 
35 µl H2O (ad 50 µl) 
 
PCR program for cloning NRD 
1. 95°C 2 min 
2. 95°C 15 sec 
3. 50°C 30 sec 
4. 68°C 3 min 36 sec, 4.->2. 40 cycles 
5. 68°C 10 min 
6. 4.0°C, pause 
 
Afterwards the complete volume of the reaction was loaded on a 2%-TBE-agarose gel and 
the fragment with the correct size was excised and purified using the MinElute Gel extraction 
kit (Qiagen). Then the fragment was digested with the same restriction enzymes used to cut 
the DNA-vector. The digested fragment was purified with the QIAquick PCR purification kit 
(Qiagen) to remove the buffer. The concentration was measured to set up the ligation reaction 
of the digested PCR-product and target vector. 
2.2.1.5.3 Mutagenesis PCR 
To perform site directed mutagenesis the QuickChange kit (Stratagene) was used to 
make point mutations in plasmid DNA. 100 ng of plasmid DNA were used as template. 
Primers containing the mutated codon were designed that 15 bp were flanking the codon both 
up- and downstream and the primer pairs are complementary to opposite strands of the vector. 
 
To setup the mutagenesis reaction, add 5 µl 10x reaction buffer, 100 ng plasmid DNA, 12.5 
pmol primer fw, 12.5 pmol primer rv, 1 µl dNTP-Mix and 1 µl PfU Turbo DNA Polymerase 
(high fidelity). 
Reaction was performed in a T3 Thermocycler (Biometra), using this program: 
1. Initial denaturation at 98 °C for 30 sec 
2. Denaturation at 95°C for 30 sec 
3. Annealing at 55 °C for 1 min,  
4. Extension for 12 min at 68°C, 4.->2. 15 cycles 
5. 4°C until removal of samples 
 
Directly after the program was finished, samples were put on ice for 2 min. Then 1 µl of 
DpnI was added and samples were incubated for 1 h at 37°C. Products were directly 
transformed into E.coli using the KCM method. 
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2.2.1.6 Agarose gel electrophoresis 
10 X TBE (3000 ml): 
   890 mM Tris base  323.4 g 
890 mM Boric acid  323.4 g 
100 mM EDTA (pH 8.0) 111.7 g 
autoclave for 20 min 
 
The quality of the DNA (RNA, recombinant plasmid DNA, PCR product) or DNA 
restriction analysis was visualized with a 1.5% TBE agarose gel. The gel was prestained with 
ethidium bromide (10 mg/ml). DNA samples were prepared in 6x loading buffer (containing 
bromophenol blue dye, MBI Fermentas). Gel was run in 1x TBE for about 30 min at 80 V. 
A standard marker (GeneRuler 100 bp DNA Ladder (1 kb) or GeneRuler DNA Ladder Mix 
(10 kb)) depending on the expected size of the band/fragment was used. DNA bands were 
visualized using the BioRad gel documentation system 
. 
2.2.1.7 Digestion of DNA with restriction endonucleases 
Digestion of DNA with restriction endonucleases was done using the appropriate 
digestion buffer and incubation temperature. DNA was digested either with one restriction 
enzyme, to verify the success of a ligation reaction, or DNA was double / triple digested using 
two restriction enzymes at one time. 
 
Enzyme(s) NotI 
XhoI 
HindIII HindII
I XhoI 
AgeI BamHI NotI 
XhoI 
PvuI 
PvuII HindIII 
EcoRI 
NsbI 
EcoRI 
HindIII 
buffer Y-Tango 
(2X) 
R(red) R(red) NEB1 G(green) Y-Tango 
(2X) 
G(green) Y-Tango 
(2X) 
Y-Tango 
(2X) 
 
Enzymes were purchased at New England Biolabs (AgeI, including buffer) or 
Fermentas Life Science (all other enzymes & buffers). 
2.2.1.8 Purification of DNA 
To purify DNA fragments after PCR or after restriction digestion the QIAquick PCR 
purification kit (Qiagen) was used. 
Add 5 fold sample volume buffer BP to the sample and pipet everything on a column 
Centrifuge for 1 min at 13000 rpm, discard supernatant 
Wash bound DNA with 750 µl buffer PE, centrifuge at 13000 rpm for 1 min, repeat last step 
to get rid of remnants of buffer PE 
To elute DNA, add 30 µl buffer EB, incubate for 10 min, place column in fresh Eppi and 
centrifuge for 1 min at 13000 rpm. Discard column and store purifed DNA at -20°C. 
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2.2.1.9 Dephosphorylation of digested plasmid DNA 
To avoid self-ligation of the linearized plasmid during subsequent ligation, it was 
subjected to dephosphorylation using the Shrimp Alkaline Phosphatase (Boehringer). 
For dephosphorylation add: 
1-2 µl digested DNA 
2 µl Shrimp Alkaline Phosphatase (1 U/µl) 
   10% (v/v) dephosphorylation buffer (10 X) 
H2O variable 
 
and incubate for 1 h at 37°C. To denature the phosphatase, incubate the reaction for 20 min at 
65°C. To remove the dephosphorylation buffer, the dephosphorylated DNA was purified 
again. 
2.2.1.10 Ligation of DNA insert and plasmid vector 
Ligation of DNA-fragments was done using T4-Ligase (Invitrogen). Digested vector 
and gene of interest were ligated using the following scheme: 
 Reaction 1 Reaction 2 Reaction 3 
Vector (in fmol) 3 15 30 
Insert (in fmol) 15 75 150 
H20  Ad 15 µl Ad 15 µl Ad 15 µl 
 
4 µl 5X ligase buffer (Invitrogen) and 1 µl T4-Ligase was added to each reaction 
The ligation was done in a T3 Thermocycler (Biometra®) using the following program: 
Lid temperature: 110°C 
8 h at 16°C, 4 h at 22°C, 2 h at 37°C and 4°C until removal of samples. 
2.2.1.11 Transformation of plasmid DNA into bacteria 
2.2.1.11.1 Production of KCM competent cells 
To produce KCM competent cells, inoculate a single colony of XL1-Blue or DH5αF 
E.coli strain in 5 ml LB media (without antibiotic) and incubate overnight at 37°C, shaking at 
250 rpm. 
1. Transfer 1 ml of overnight culture into 150 ml of fresh LB media 
2. Let the bacteria grow until they reach an OD600 of 0.6 
3. Centrifuge cell suspension for 10 min at 500 rpm at RT 
4. Discard supernatant 
5. Resuspend pellet in 15 ml (1/10 volume) buffer TSB 
6. Incubate for 10 min on ice 
7. Aliquot suspension (500 µl each) into Eppendorf safelock tubes 
8. Freeze Eppis in liquid nitrogen and store in -80°C 
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2.2.1.11.2 Transformation of KCM competent cells 
For transformation of plasmid DNA (ligation mix or plasmid DNA from Mini-
preparation) KCM competent cells were used. The transformation was done as follows: 
1. Pre-warm appropriate volume of SOC media at 37°C (1 ml for 1 transformation) 
2. Add 20 µl of ligation mix or 10-20 ng of super-coiled plasmid DNA to 20 µl KCM 
buffer 
3. Mix and put on ice 
4. Take KCM competent cells from -80°C and thaw them on ice 
5. Add 100 µl competent cells to DNA-KCM buffer mix 
6. Incubate on ice for 10 min (for re-transformation) or 50 min (ligation mixture) 
7. Add 1 ml pre-warmed SOC media 
8. Incubate for 1 h at 37°C with shaking at 300 rpm  
9. Pellet transformation mixture and plate on LB agar, containing appropriate antibiotic 
10. Incubate plates upsite down overnight at 37°C 
11. For retransformation and subsequent Midi preparation, inoculate 50 ml LB (including 
antibiotic) directly with transformation mixture 
2.2.1.12 Generation and production of recombinant baculovirus 
To generate recombinant baculovirus the purified recombinant Bacmid-DNA has to be 
transfected into insect cells. For that split Sf9-cells to a densitiy of ~ 3x 10^6 cells (~ 0.25 ml 
of a confluent 25ml bottle). Add 4.75 ml Sf9-Media (27°C) (Media for transfection w/o FCS 
and antibiotics) and control the cells for attachment after 1 h incubation. 
To transfect the Sf9 cells, prepare 2 Eppis using the following table: 
3 µg (30 µl) Bacmid-DNA 1 
100 µl IPL41 w/o serum and antibiotics 
(Insect.Media) 
18 µl Cellfectin® 2 
100 µl IPL41 w/o serum and antibiotics (Insect 
Media) 
 
Mix reaction 1 & 2 and incubate for 30 min at RT 
Remove media from Sf9-cells and add 5 ml IPL41 (w/o antibiotics and FCS) 
Add the mix (1&2) to the cells and incubate ON and change the cell media the following day. 
Let transfected cells grow for 6 days, to amplify virus. Centrifuge cells, discard the Sf9-cell 
pellet but store the supernatant (Baculo virus supernatant, BVSN). 
Take 200 µl BVSN and infect Sf9-cells (2 bottles with Sf9 cells) and grow cells for 4 
days to amplify virus. Harvest cells, centrifuge, freeze cell pellet and store supernatant at 4°C 
(stock virus 1, SV1)  
Take 200 µl SV1 and infect 2 bottles with fresh Sf9-cells and grow them for 4 days. 
Harvest cells, centrifuge, freeze cell pellet and store supernatant at 4°C (stock virus 2, SV2)  
Prepare 6 bottles with Sf9-cells. Infect 5 bottles with 200 µl SV2 (A) and one bottle 
with 500 µl SV2 (P). Grow cells, harvest bottle P after 60 –72 h, lyse cell pellet. Purify 
protein using Ni-beads and verify protein expression (Coomassie-Gel). Harvest bottles A after 
5-6 days, centrifuge and store supernatant at 4°C (working virus, wv) and pellet at –80°C. 
Infect Sf9-cells with 500 µl wv and optimize culturing time for optimal protein expression.  
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2.2.2 Methods in cell biology 
2.2.2.1 Cell culture 
 
Cryopreservation 
For long time storage cells were frozen in DMSO and stored in liquid nitrogen. 
Briefly, medium was removed; cells were washed with PBS and trypsinized (2 ml trypsin per 
10cm dish). Trypsinized cells were transferred into a 15 ml tube, containing 8 ml cell media 
and centrifuged for 3 min at 200 rpm. Supernatant was removed, 1.8 ml media was added, 
cells carefully resuspended and aliquoted into 2 cryo-tubes, each containing 100 µl DMSO. 
Cryo-tubes were kept in –20°C for 2 h, transferred to –80°C for 5 h and finally stored in 
liquid nitrogen. 
Thawing of cryo-preserved cells: suitable cell media was directly poured into a bottle 
for culturing cells (10 ml media) and placed in a incubator; 9 ml cold media was added into a 
15ml tube. Cryo-tubes were taken out of the liquid nitrogen and thawed in a 37°C-waterbath 
(shaking by hand) until the ice has the size of a pea. Cell suspension was transferred into the 
15ml tube (with cold media) and centrifuged for 3 min at 200-300 g. Supernatant was 
removed, cells carefully resuspended in fresh media and transferred into the cell culture bottle 
(with pre-warmed media, in incubator). 
 
2.2.2.2 Lipotransfection 
 
Transfection of mammalian cells was done using Fugene6 (Roche Diagnostics). 
Briefly, Fugene6 was added to 180 µl serum-free medium and incubated for 5 min. Then 500 
ng DNA was added, mixed and incubated for 30 min. For transient transfection, medium of 
cells was changed to serum free media. The Fugene6-DNA complex was added to the cells, 
incubated overnight and serum free medium was changed to complete medium. For stable 
transfection the medium was not changed to serum free media. The Fugene6-DNA complex 
was directly added to the cells and incubated overnight. Then the medium changed to fresh 
complete medium. 
 
2.2.2.3 Transfection with magnetic beads 
 
SH-SY5Y cells were split in 60mm dishes and grown until a confluence of 60-80% 
was reached. 6.6 µg DNA was mixed with media (w/o FCS and supplements) and 6.6 µl 
MATra-solution and incubated for 20-30 min at room temperature. 
After incubation media was changed, 4 ml fresh media (w/o FCS and supplements) and the 
DNA/MATra-Mix was added and incubated for 15 min on a magnetic plate at 37°C. 
Afterwards media was changed and fresh media (complete with FCS and supplements) was 
added. 24-48 h post transfection, cells were inspected for transfection and antibiotic was 
added for selection of stably expressed DNA in these cells. 
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2.2.3 Methods in protein chemistry 
 
2.2.3.1 Production whole cell lysate 
 
4x Lysis buffer: 
200 mM Tris / HCl, pH 7.5 
4 mM EDTA 
4 mM β-mercaptoethanol 
600 mM NaCl 
4% Igepal 
 
According to the size of the cell culture dish 1X lysis buffer is added to the frozen cell 
pellet (1 ml (10cm dish), 0.5 ml (6cm dish) or 250 µl (3.5cm dish)) and resuspended. The 
lysate was incubated at 4°C, 15 min on a rotating wheel. The samples are then centrifuged at 
14000 g, 15 min, 4°C (Beckmann Avanti), the supernatant is transferred into a new tube. 
2.2.3.2 Protein quantification (Bradford) 
 
Protein quantification of whole cell lysate was done using the BioRad Protein assay. A 
dilution series of a standard ([BSA] = 1 mg/ml) was prepared as follows: 
 
Standard No Final concentration 
(µg/ml) 
BSA-solution (µl) H2O (ml) 
1 0 - 1 
2 1 1 0.999 
3 2 2 0.998 
4 5 5 0.995 
5 10 10 0.990 
6 15 15 0.985 
7 20 20 0.980 
8 25 25 0.975 
 
For each sample, 2 different dilutions are prepared in an amount suitable for triple 
measurement. 
50 µl BioRad-Reagent are added to each well of a ELISA-microtiter-plate (NUNC-
IMMUNOTMMODULE 160 BAG or 80 BAG) and 200 µl sample resp. standard are added and 
incubated for 10 min. Protein concentration is measured at 595 nm in a ELISA-Reader (Emax 
precision microplate reader, Molecular Devices) and quantified using the program 
SOFTmax®PRO. 
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2.2.3.3 Methanol/acetone precipitation of proteins 
To concentrate aqueous protein solutions they are mixed with their 4 fold volume of a 
methanol/acetone solution, incubated at 37°C for 15 min and centrifuged at 14000 rpm, RT, 
15 min; the supernatant removed and the pellet dried at 37°C. The dry pellet is then dissolved 
in 20 µl 1X sample buffer. 
2.2.3.4 TCA precipitation of proteins 
100% TCA (w/v): 
100 g TCA (trichloroacetic acid) 
45.4 ml H20 
 
1. Add 1/11 of sample volume 100% TCA to sample (medium, supernatant) (110 µl 
100% TCA to 1 ml medium) 
2. mix by inverting the tube several times 
3. incubate for 10 min at room temperature 
4. centrifuge for 15 min, max speed, remove supernatant 
5. add 200 µl 10% TCA to pellet 
6. mix by vortexing, centrifuge for 15 min, max speed, remove supernatant 
7. add 200 µl 10% TCA to pellet 
8. mix by vortexing, centrifuge for 15 min, max speed, remove supernatant  
9. add 200 µl ice cold acetone 
10. mix by vortexing, centrifuge for 15 min, max speed, remove supernatant 
11. dry pellet at room temperature and dissolve in sample buffer (containing β-
Mercaptoethanol)  
 
2.2.3.5 SDS PAGE  
2.2.3.5.1 Preparation of polyacrylamide gels 
 
Buffer and solutions 
 
30% Acrylamid / BIS (Roth) 
 
Separating gel buffer: 
750 mM TRIS / HCl (18.2 g / 200 ml) adjust with 5 M HCl to pH 8.8 
Stacking gel buffer: 
250 mM TRIS / HCl (6.1 g / 200 ml) adjust with 5 M HCl to pH 6.8 
SDS-Solution: 
10% (w/v) SDS in H2O (1 g / 10 ml) 
PER- Solution: 
10% (w/v) Ammonium peroxydisulfate in H2O (1 g / 10 ml) 
TEMED: 
N,N,N´,N´-Tetramethylethylendiamin (Roth) 
5x gel running buffer: 
125 mM TRIS (15.31 g / l) / 960 mM Glycine (72.1 g / l) 
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4x Sample buffer: 
500 mM TRIS / HCL (6.05 g / 100 ml), pH 6.8 
8% (w/v) SDS (8 g / 100 ml) 
40% Glycerol (40 g / 100 ml) 
0.005% (w/v) Bromphenolblue (1 ml Bromphenolblue in H2O) 
add H2O to a total volume of 80 ml and adjust to pH 6.8 with HCl  
20% mercaptoethanol (add prior to use) 
 
The proteins were separated using the method of Laemmli (Laemmli, 1970). The gels 
were done using the following scheme (for 2 gels each) 
 
Resolving gel Stacking gel  
5% 7% 10% 12.5% 3% 4% 
30% Acrylamide / 
BIS 
2 ml 2,8 ml 4 ml 5 ml 0.5 ml 0.67 ml 
Resolving gel buffer 6 ml 6 ml 6 ml 6 ml - - 
Stacking gel buffer - - - - 2.5 ml 2.5 ml 
H2O 3.8 ml 3.0 ml 1.8 ml 0.8 ml 1.9 ml 1.73 ml 
10% SDS-solution 0.12 ml 0.12 ml 0.12 ml 0.12 ml 0.05 ml 0.05 ml 
PER-solution 0.06 ml 0.06 ml 0.06 ml 0.06 ml 0.04 ml 0.04 ml 
TEMED 24 µl 24 µl 24 µl 24 µl 10 µl 10 µl 
Bromphenolblue - - - - 15 µl 15 µl 
 
The glass and metal plates were cleaned with 70% EtOH and prepared for the gel 
caster system. 4.6 ml of the desired resolving gel solution was poured into the gel caster and 
immediately overlaid with isopropanol to get a smooth resolving gel surface. After 
polymerization the isopropanol is carefully removed with H2O. Remaining H2O is soaked out 
with a small stripe of Whatman paper. A suitable gel comb is inserted and the stacking gel 
solution is added. 
2.2.3.5.2 Preparation of protein samples for SDS PAGE 
 
The protein samples are either precipitated (in case of lower protein concentration) 
with methanol / acetone precipitation and dissolved in 1 X sample buffer or the protein 
samples (in case of higher protein concentration) are directly dissolved in 2 X sample buffer. 
To quantify the molecular weight of the samples 5 µl of molecular standards were diluted in 
15 µl 1 X sample buffer.  
 
The following markers were used: 
 
Low Molecular Weight (LMW, GE-Healthcare): 
Contains a mixture of these proteins: 
Phosphorylase b Mw = 97 kDa 
Albumin Mw = 66 kDa 
Ovalbumin Mw = 45 kDa 
Carboanhydrase Mw = 30 kDa 
Trypsininhibitor Mw = 20.1 kDa 
α-Lactalbumin Mw = 14.4 kDa 
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Precision Prestained Plus (BioRad): 
Contains 10 prestained recombinant proteins in the following sizes: 
10 kDa, 15kDa, 20 kDa, 25 kDa, 37 kDa, 50 kDa, 75 kDa, 100 kDa, 150 kDa, 250 kDa. 
 
Prepared samples and marker are boiled for 5 min and spun down shortly. The 
prepared gels are placed into the gel chamber, fastened and the upper and lower chamber is 
filled with running buffer. After removal of the gel comb the sample wells are washed using a 
syringe (Hamilton) and samples are applied. 
The gel chamber is connected to the power supply and the samples are electrophoretic 
separated at 80 V until they reach the separation gel. Then the voltage is increased to 120 V 
until the (coloured) running front of the samples has reached the bottom of the gel. 
After finishing the electrophoresis the glass plates are removed from the gel, the 
stacking gel is cut off and discarded. The remaining gel can be stained with Coomassie Dye 
or transferred onto a nitrocellulose membrane for Western Blotting. 
 
2.2.3.5.3 Coomassie-staining of SDS-gels 
 
Staining solution: 
0.25% (w/v) Coomassie Brilliant Blue R250 (2.5 g/l) 
10% (v/v) pure acetic acid 
45% (v/v) methanol 
in H2O 
 
Destaining solution: 
10% (v/v) pure acetic acid 
30% (v/v) methanol 
in H2O 
 
For staining of polyarcylamide gels the gels are placed into staining solution on a 
rocker for at least 30 min. To destain the background, gels are transferred into destaining 
solution, covered with a small piece of foamed material, and rocked until sufficient 
destaining. Afterwards the gels are dried overnight using a gel drying frame. 
 
2.2.3.5.4 Blotting and immunostaining (Western Blot) 
 
5 X Transfer buffer: 
125 mM TRIS (15.1 g / l) / 960 mM Glycin (72.1 g / l) 
1 X Transfer buffer: 
20% (v/v) methanol, 20% (v/v) 5 X Transfer buffer, 60% (v/v) H2O 
Ponceau-S-solution: 
0.2% (w/v) Ponceau S (Boehringer, Mannheim) in 3% acidic acid 
Washing buffer: 
PBS / Tween 0.05%: 
100 ml 10 X PBS 
900 ml H2O 
0.5 ml Tween®20 
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The polyacrylamide gel is equilibrated for blotting in the transfer buffer for a few 
minutes, placed onto a gel-sized nitrocellulose membrane (HybondTM-C Extra, Nitrocellulose, 
45 Micron). 
Similarly, two blotting papers (Gel-Blotting Paper GB 003, Schleicher & Schuell) are 
equilibrated in transfer buffer, placed directly into the semidry-blot cell (Trans-Blot SD; BIO-
RAD, München), and covered with two equilibrated blotting papers.  
The blotting is done at 15 V, 200 mA (for 1 gel) or at 15 V, 400 mA (high voltage; for 
more than 1 gel). The transfer of proteins is controlled with Ponceau-S-solution; markers as 
they are not prestained – are marked and the membrane is destained in H2O. 
To block unspecific binding the membrane is blocked with Rotiblock® (1:10 in H2O) 
or non-fat-dry milk (3.5 or 5% w/v) for at least 1 h. 
After blocking, the membrane was incubated with the antibody directed against the 
specific protein. The duration for the incubation with the primary antibody was adjusted to the 
target protein and the antibody. Usually, the incubation was done for 1 h or ON. 
After the incubation with the primary antibody the membrane was washed three times 
(15, 10 and 5 min) with PBS-Tween 0.1% and incubated with the secondary antibody (HRP 
conjugated) for 1 h. Then the membrane was washed as done with the primary antibody, 
incubated with the ECL reagent (Supersignal West Pico kit) for 5 min, and exposed to X-Ray 
films. Films were scanned with a GS-800 Calibrated Densitometer and quantified using the 
Biorad Quantitiy One Program and if desired, statistical analysis was done using SIGMA Plot 
8.0. 
2.2.3.5.5 Stripping of membranes for reprobing 
For reprobing of Western Blot membranes with a different primary antibody, the 
membranes have to be cleaned from the firstly used primary antibody (stripping).  
Stripping buffer for removal of antibodies: 
 
62.5 mM TRIS/HCl pH 6.7 (0.757 g / 100 ml) 
2% (w/v) SDS (2 g / 100 ml) 
100 mM β-Mercaptoethanol (800 µl / 100 ml) 
 
After detection with first antibody, membranes are washed with (PBS /Tween 0.1%) 
and incubated for 30 min at 50°C covered in stripping buffer. After incubation, membranes 
are carefully washed and incubated with blocking buffer. 
2.2.3.6 Purification of His-tagged proteins 
Purification of His-tagged proteins from Sf9-cells was done using a modified protocol 
as published in Ma et al 2001. 
Lysis buffer (200 ml): 
   50 mM TrisHCl   (1.21 g) 
   150 mM KCl    (2.24 g) 
   pH 8.5 
Washing buffer (200 ml): 
   50 mM TrisHCl   (1.21 g) 
   2 M NaCl    (23.38 g) 
   pH 8.5 
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Elution buffer (200 ml): 
   50 mM TrisHCl   (1.21 g) 
   250 mM Imidazole (MW 68.08) (3.40 g) 
   pH 8.5 
 
 His-HsNRD (example) 
Number of bottles- harvested 
for pellet (KF) 
6 (example) 
Lysis buffer (KF x 3ml= VL) 18 ml 
Protease inhibitors: 
Leupeptin (VL x 1 µl/ml) 
Pepstatin A (VL x 1 µl/ml) 
Aprotinin (VL x 1 µl/ml) 
Pefablock SC (VL x 2.5 µl/ml) 
Benzamidine (VL x 2 µl/ml) 
 
18 µl 
18 µl 
18 µl 
45 µl 
36 µl 
Nickel Agarose Beads 
(KF x 100 µl = VB) 
600 µl 
Washing buffer (KF x 1.5 ml) 
(Sf9-Lysis buffer without protease inhibitors) 
9 ml 
Elution buffer (=VB ) 600 µl 
 
Calculate and prepare desired amount of Sf9 lysis buffer, washing buffer, nickel agarose 
beads using the example shown above. Purify His-tagged protein: 
1. add lysis buffer (including protease inhibitors) to cell pellet 
2. homogenize cell pellet using a Ultraturrax (IKA T25 ) 
3. centrifuge lysate for 30 min, 4 °C, at 35000 x g (Sorvall centrifuge 20000 rpm, Sorvall 
SS34 rotor) 
4. during centrifugation equilibrate Ni-Agarose-Beads by washing them 3 times with 
2VB (see table) at 2000xg, for 5 min at 4°C 
5. after last washing step resolve Ni-Beads in 0.5VB Lysis buffer 
6. take supernatant of centrifuged lysate, take aliquot for SDS-PAGE [Input I] 
7. add Ni-agarose- beads to supernatant and incubate on a rotating wheel for 1 h at 4 °C   
8. centrifuge at 500-1000 xg (1700 rpm), for 10 min at 4°C; take aliquot for analysis [D] 
9. wash 3 times with VL (see table) lysis buffer, take aliquots for gel [L1, L2, L3] 
(centrifuge at 500-1000 xg (1700 rpm), 4°C for 10 min each time) 
10. add washing buffer, centrifuge at 500-1000 xg (1700 rpm), for 10 min at 4°C, take 
aliquot for gel: W) 
11. to elute protein add elution buffer (VB see table) and shake on ice for 15 min; 
centrifuge at 3300 rpm, 4°C for 5 min, take aliquot (E1) 
12.  add 1 VB  elution buffer, shake on ice for 10 min, centrifuge at 3300 rpm, 4°C for 5 
min, take aliquot (E2) 
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Run SDS PAGE with aliquots of I, D, E1 and E2 an stain with Coomassie to verify 
efficiency of purification and expression of desired His-tagged protein. 
When the protein is expressed in sufficient amounts (verified by Coomassie-staining), 
total amounts of elution E1 and E2 were pooled and the buffer was exchanged with storage 
buffer as follows: 
Storage buffer: 
 20 mM KH2PO4, 
 10 % Glycerol,  pH 7.0 
For washing add 20 ml storage buffer on the column (PD10 column, GE-Healthcare) 
and let buffer flow through the column. 
Meanwhile adjust the pooled protein to a volume of 2.5 ml using storage buffer and 
apply it to the column. 
Collect fractions and check the protein concentration using 12.5 µl Bradford reagent, 
45 µl H2O and 5 µl of sample. Use the same Bradford assay program but set samples as 
standard (no BSA standards required). Pool fraction with highest protein concentration 
(highest peak in Bradford assay) and apply to an equilibrated (washed one time with storage 
buffer, centrifuged for 5 min at 4000 rpm) concentrator (Centricon-10 (Millipore) 
concentrator). Concentrate protein approximately to 1ml final volume and quantify final 
concentration (Standard Bradford protein assay including BSA dilution series). Prepare 
aliquots of concentrated protein, freeze in liquid nitrogen and store protein at – 80°C. 
 
2.2.3.7 Purification of GST-tagged proteins 
 
Lysis buffer (200 ml): 
50 mM TRIS (MW 121.1)    1.21 g  
150 mM NaCl (MW 58.44)   1.75 g 
10 mM NaF      20 ml 100 mM NaF 
1% TRITON X100     2 ml  
adjust to pH 7.5 using HCl  
 
4 M NaCl  
NaCl (MW 58.44)     23.4 g 
ad 100 ml using H2O 
 
1 M NaCl /Lysis buffer (30 ml): 
   7.5 ml 4x Lysis buffer (modified RIPA-buffer) 
6.375 ml 4 M NaCl 
16.125 ml H2O 
10X TRIS/NaCl (200 ml) 
500 mM TRIS (MW 121.1)    12.11 g 
1 M NaCl (MW 58.44)    11.69 g 
   pH 8.0 with HCl  
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storage buffer (200ml):  
50 mM TRIS/HCl pH 8.0  
100 mM NaCl 
20 ml 10xTRIS/NaCl  
1 mM β-mercaptoethanol    16 µl  
20% Glycerol  
 
 GST-p42IP4 (example) 
Number of bottles- harvested for 
pellet (KF) 
6 
Sf9 lysis buffer(Triton) (KF x 3 ml = 
VL) 
18 ml 
Protease inhibitors: 
Leupeptin (VL x 1 µl/ml) 
Pepstatin A (VL x 1 µl/ml) 
Aprotinin (VL x 1 µl/ml) 
Pefablock SC (VL x 2.5 µl/ml) 
Benzamidine (VL x 2 µl/ml) 
 
18 µl 
18 µl 
18 µl 
45 µl 
36 µl 
Glutathion Sepharose Beads 
(KF x 100 µl=VB) 
600 µl 
Washing buffer (KF x 1.5 ml) 
1 M NaCl / Lysis buffer (modified 
RIPA-buffer) 
9 ml 
 
Calculate and prepare desired amount of Sf9 lysis buffer, washing buffer, Glutathione 
sepharose beads using the example shown above. Purify GST-tagged protein: 
 
1. Add Sf9-lysis buffer (Triton) containing Protease inhibitors to cell pellet 
2. homogenize cell pellet using a Ultraturrax (IKA T25 ) 
3. centrifuge homogenate for 20 min, 38400 xg (17000 rpm) (Sorvall AH629 Rotor) at 
4°C 
4. equilibrate GSH-beads: wash 1 time with VB and 2 times with 2xVB Sf9-Lysis buffer 
(Triton) for 5min, 500 xg at 4°C 
5. take supernatant from cell homogenate (after centrifugation, step 3) add 100 µl 
Glutathion Sepharose Beads per bottle (=VB ) and incubate for 1 h at 4°C on a rotating 
wheel 
6. centrifuge at 500-1000 xg (1700 rpm), 4°C for 7 min [after Beads D] 
7. wash beads 3 times with Sf9-lysis buffer (Triton) [aliquots L1, L2, L3] 
8. resuspend beads in 1 M NaCl / lysis buffer (modified. RIPA-buffer), shake on ice for 
15 min, centrifuge [aliquot W] 
9. adjust beads to a final concentration of 50% slurry (use ½ VB) Sf9- storage buffer 
10. run SDS-PAGE [input, D, GST-beads, L1/2/3, W] to verify quality of purification 
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2.2.3.8 Pull-down recombinant His tagged proteins with GST-tagged proteins 
 
Adjust His - tagged protein to a final concentration of 50 µg/ml using lysis buffer/BSA  
Prepare six samples using the following table: 
 
 
1. Incubate for 2 h at 4°C on a shaker 
2. Centrifuge samples for 5 min at 1000xg 
3. wash 2 times with 200 µl lysis buffer/BSA at 1000xg, 4°C for 5 min 
4. wash 2 times with 200 µl lysis buffer without BSA at 1000xg, 4°C for 5 min 
5. incubate with 100 µl lysis buffer containing 1 M NaCl for 15 min at 4°C 
6.  to elute bound proteins; centrifuge at 13000xg, 4°C for 5 min 
7. precipitate eluted proteins using methanol/acetone precipitation 
2.2.3.9 Immunprecipitation 
 
Take 500 µg lysate, add anti-GFP (5-10 µl), incubate for 4 h at 4 °C on rotating wheel 
Add Sepharose-A or –G-beads, incubate overnight at 4°C on rotating wheel 
Wash 3 times with 1X lysis buffer (1 ml/ tube) (with or without Pi), centrifuge at 500g for 5 
min (Beckmann 2500 rpm, 4°C) 
Leave 10-20 µl supernatant, add 2X (or 4X) sample buffer, mix 
Boil samples for 5 min, centrifuge (max speed), take supernatant for analysis on SDS-PAGE 
2.2.3.10 Far Western Blot 
 
Far Western Blots, including the buffers used, were done according to a modified 
protocol published previously (Wu et al., 2007). To allow tubulin polymerization, the amount 
of glycerol was increased to 4 M in the protein binding buffer, as it was published before 
(Shelanski et al., 1973). For experiments, using nonpolymerized tubulin, the protocol was 
performed as described before, except that after adding of protein binding buffer, blots were 
kept on a shaker at 4°C for 1.5 h, followed by addition of hsNRD1 and tubulin in 4°C, 
without prior exposure to heated buffer. 
Milk-solution: 
 3g milk powder in 14.7 ml ddH2O 
Buffer AC: 
 14.7 ml milk solution 
 3 ml NaCl (5 M) 
 3 ml Tris (1 M), pH 7.5 
 0.3 ml EDTA 0.5 M 
 1.5 ml Tween-20 (10%) 
 15 ml Glycerol 
 150 µl DTT (1 M) 
Reaction (µg His - 
tagged protein) 
µl lysis buffer/BSA  X µl of His-tagged 
protein (50 µg/ ml) 
µl Beads  
1 (0) 90 µl 0 20 µl GST 
2 (1) 70 µl 20 µl 20 µl GST 
3 (0) 90 µl 0 20 µl GST-tagged protein 
4 (0,1) 88 µl 2 µl 20 µl GST-tagged protein  
5 (0,5) 80 µl 10 µl 20 µl GST-tagged protein  
6 (1) 70 µl 20 µl 20 µl GST-tagged protein 
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buffer 6: 
 18.75 ml Guanidine-HCl (8 M) 
 6.275 ml buffer AC 
buffer 3: 
 9.3 ml Guanidine-HCl (8 M) 
 10.37 ml H2O 
 6.275 ml buffer AC 
buffer 1: 
 3.13 ml Guanidine-HCl (8 M) 
 15.62 ml H2O 
 6.275 ml buffer AC 
buffer 0.1: 
 310 µl Guanidine-HCl (8 M) 
 18.44 ml H2O 
 6.275 ml buffer AC 
buffer 0: 
 18.75 ml H2O 
 6.275 ml buffer AC 
 
buffer 6: 30 min, RT; buffer 3: 30 min, RT; buffer 1: 30 min, RT; buffer 0.1: 30 min, 4°C; 
buffer 0: overnight, 4°C 
 
blocking: 
 
cut membranes and block in Rotiblock® during tubulin polymerization (5 h); remove 
Rotiblock ® and add 1050 µl protein binding buffer, incubate box 1 and box 2 for 1.5 h at RT 
(shaker), incubate box 3-8 for 1.5 h at 4°C (=during incubation of tubulin with NRD) 
 
protein binding buffer: 
Milk-solution: 
 0.2 g milk powder in 6.47 ml ddH2O 
Buffer AC: 
 6.47 ml milk solution 
 200 µl NaCl (5 M) 
 200 µl Tris (1 M), pH 7.5 
 20 µl EDTA 0.5 M 
 100 µl Tween-20 (10%) 
3 ml Glycerol (30% ~ 4 M for tubulin polymerisation without GTP) 
 10 µl DTT (1M) 
- incubate for box 2 tubulin+buffer (ad 200 µl) for 5 h at 37°C in a 1.5 ml Eppi 
- add hsNRD1 [210 µg/µl] (reaction: 1, 2) and incubate for 1.5 h at 20°C 
1 2 3 4 5 6 7 8
NRD 10 µg 10 µg
hsNRD1 hsNRD1
tubulin 0 10
NRD (µl) 48 48
tubulin (µl) 0 5
buffer AC (ad 200 µl) 152 147
adjust to 1.25 ml (µl AC) 1050 unpolymerized tubulin
- 
add hsNRD1+tubulin / NRD + nonpolymerized tubulin (reaction: 3-8) mixture to blocked 
membrane 
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- incubate overnight (4°C, shaker) 
- wash blots 8 times, each 15 min with PBS Tween 0.1% 
- incubate with NRD antibody (N20 1:2000) for 2h at RT, wash 3 times (15, 10, 5 min) 
- incubate with mouse anti goat-HRP 1:20000 for 1h at RT, wash 3 times (15, 10, 5 min), 
detection see chapter 2.2.3.5.4 
- strip membranes, block in Rotiblock® 
- incubate with p42IP4-antibodies: 117-2 1:5000; goat anti mouse-HRP 1:20000, detection see 
description above and chapter 2.2.3.5.4 
2.2.3.11 Fluorescence measurements 
The quenched substrate (abz =Abz-Gly-Gly-Phe-Leu-Arg-Arg-Val-Gly-Gln-EDDnp) 
derived from bovine adrenal medulla peptide ((Csuhai et al., 1999b); custom synthesis 
BACHEM, Switzerland) was used to monitor the cleavage activity of the purified NRD at 
34°C, in 20 mM potassium phosphate, pH 7 in a 200 µl reaction using a TECAN-fluorescence 
reader with excitation wavelength 320 nm and emission wavelength 420 nm. 
2.2.3.12 Cleavage assay p42IP4 
To test, whether p42
IP4
 can serve as a substrate for NRD, equimolar amounts (80 nM) 
of both proteins were incubated for 1, 4, 7 and 10 hours at 37°C in potassium phosphate-
buffer, pH 7 (Csuhai et al., 1999b). The reaction was stopped by adding 4X sample buffer, 
containing β-mercaptoethanol, 5 min boiling and immediate storage at –20°C. Afterwards 
samples were boiled and loaded onto a 12.5% SDS-PAGE. Western Blot was done using the 
following p42IP4 specific antibodies 117-2, Rai-1 and Rai-2. Secondary antibodies: goat anti 
mouse and goat anti rabbit. 
2.2.4 Confocal microscopy 
 
Cells were fixed with 4% paraformaldehyde solution (PFA)(4% sucrose, 120 mM Na-
phosphate buffer, pH 7.4) for 30 min at RT, after removal of PFA, fetal serum blocking buffer 
(FSBB; 6% FCS, 20 mM Na-phosphate buffer, 0.45 M NaCl, 0.1% Triton-X100, pH 7.4) was 
added for 20 min to block unspecific binding. Coverglasses were washed three times in low 
salt (0.15 mM NaCl and 10 mM phosphate), three times in high salt (0.5 mM NaCl and 20 
mM phosphate) buffer. 
For SH-SY5Y cells primary antibodies were used according to the experimental setup: 
for detection of NRD and p42IP4 (goat anti-NRD N20 1:100, rabbit polyclonal anti-p42IP4 
antibody 1:200, diluted in FSBB), for detection of NRD and tubulin (goat anti-NRD N20, 
1:100 and mouse anti β-tubulin I antibody 1:500) were added ON. 
GFP- transfected SH-SY5Y cells were incubated with primary antibodies (goat anti-NRD 
N20, 1:100 and mouse anti β-tubulin I antibody 1:500, diluted in FSBB) overnight at 4°C. 
Cells were washed three times with high salt buffer and incubated with the appropriate 
(directed against the species of the primary antibody) secondary Alexa-dye conjugated 
antibody. For example for NRD and tubulin staining: Alexa 555 donkey anti-goat antiserum 
for 90 min at RT, wash three times with high salt buffer and incubate with Alexa 633 goat 
anti-mouse antiserum (Molecular Probes) for 90 min at RT. 
After incubation with secondary antibodies, cells were washed once with high salt buffer, 
then with 120 mM Na-phosphate, and once with 5 mM Na-phosphate. After washing with 
PBS (pH 8.9), cover glasses were drained and mounted onto microscope slides. Fluorescence 
images were captured sequentially with excitation at 488 nm, 543 nm and 633 nm using a 
LSM510 laser scanning confocal microscope (Carl Zeiss, Jena, Germany) and analyzed using 
the program Lsmix (Carl Zeiss, Jena, Germany).  
Results 
 50 
3 Results 
3.1 Cloning of human NRD from HEK293 cells 
To study the interaction between NRD and p42IP4 in vivo and in vitro it was necessary 
to clone human NRD from cDNA. In exploratory experiments, different human cell lines 
were tested for the expression level of NRD with RT-PCR. 
Based on the results from these experiments HEK293 cells were chosen for cloning of 
HsNRD1 via RT-PCR. The obtained fragment transcribed from HEK293 cDNA (see 2.2.1.5.2 
for details) was cloned into pBSKII. Blue-white screening for successful cloning revealed 16 
positive clones for NRD. Further sequencing confirmed the complete sequence of human 
NRD. Nevertheless, using BLAST no gene sequence could be found, which was 100% 
identical to the clones obtained from HEK293. Several hsNRD1/2 sequences, were not only 
different from our clones but they also differed among themselves.  
For production of recombinant NRD protein, later to be used for in vitro experiments, 
human NRD was subcloned into vectors suitable for expression in Sf9-insect cells and 
mammalian cells. 
Position Reference Nucleotide Reference Nucleotide clones 
from HEK293 
205 c g 
206 g c 
500 c t 
502 a g 
1054 g a 
1350 c a 
1919 t a 
1597 c t 
2766 t c 
3561 t c 
3606 g a 
3636 a t 
3637 t a 
Table 3.1 Comparison of clones from HEK293 with the reference sequence NM_002525.1  
Several clones obtained with from RT-PCR cloning from HEK293 cells were compared with the reference 
sequence. 
For future reference, the sequence NM_002525.1 is used as reference sequence. This 
sequence comprises the complete human NRD sequence, including the specific insertion for 
the human NRD2 isoform. Sequencing of the clones revealed 13 differences in the nucleotide 
sequence compared to the reference sequence, as shown in Table 3.1. 
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Fig. 3.1 Translation of the nucleotide sequence of the HEK293 clone into an amino acid sequence.  
The sequenced nucleotide sequence (see also Table 3.1) was translated. The highly conserved HFLEH-motif is 
underlined.  
 
We then used ENSEMBL to translate the nucleotide sequences into amino acid 
sequences. Comparison of this translated sequence with the amino acid sequence of the 
translated reference sequence showed a difference only in one amino acid (isoleucine instead 
of valine) close to the HFLEH-motif (Fig. 3.1 HFLEH MI). We were uncertain, whether the 
Ile is a mutation close to the highly conserved HFLEH-motif. To address this issue we 
checked the GenBank for other protein sequences of NRD. Nine different human NRD amino 
acid sequences can be found in GenBank with only one sequence displaying 1218/1219 
identities (CAH74099.1) with our sequence. Most importantly, all nine sequences differ in 
their sequence, but they do not contain an exchange of this valine to isoleucine. Moreover, 
eight sequences had differences in their sequences ranging from two up to seven amino acids, 
which as mentioned before, occur at positions different from the position of the valine close to 
the HFLEH-motif. To confirm further that the isoleucine is indeed a mutation, the genomic 
sequence was controlled at that position. As expected, also the genomic sequence displayed a 
valine there. 
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Unfortunately, sequencing of other clones gave few clones without this mutation but 
all with mutations at different positions even within the DAC, the HFLEH-motif or they 
lacked numerous nucleotides. We therefore decided to repair the clone using site directed 
mutagenesis, thereby exchanging the isoleucine with valine. To exclude any additional 
changes, not only the nucleotide sequence close to the HFLEH-motif was sequenced but the 
complete sequence of the clone. This clone (HsNRD1 in pBSKII) was then used for cloning 
into other vectors for expression in mammalian or insect cells and as basis for the production 
of NRD mutants. 
In the process of cloning human NRD1 we also found one NRD clone, which had the 
nucleotide insertion that is typical for the NRD2 isoform. Comparison with the reference 
sequence NM_002525.1 and the NRD1, cloned by us from HEK293 cells, revealed that the 
NRD2 clone lacked several nucleotides. The missing nucleotides were at different positions, 
which resulted in two frameshifts, the latter readjusted the reading frame to normal mRNA 
translation. Due to the weak expression of NRD2 in HEK293 cells (see Fig. 3.2 upper band in 
the HEK control lane) and the otherwise identical sequence to our HEK293 clones and the 
reference sequence, together with difficulties to reproduce the cloning of hNRD2, we 
performed site directed mutagenesis. We inserted the missing nucleotides (hNRD2 primers, 
see chapter 2.1.3; added nucleotides in bold) into the clone for NRD2. The NRD2 clone is 
now identical to the NRD1 clone and additionally contains the NRD2 insertion as published 
in NM_002525.1.  
 
Fig. 3.2 Cloning of human NRD. Agarose Gel with EtBr staining 
PCR with positive clones from cloning hNRD from HEK293 was performed according to Fontes et al. 2005. 
Lanes 1-7 and 9-15 show positive signals for NRD1 (385 bp) as indicated with the lower arrowhead. Lane 8 
shows a signal for NRD2 (385bp) as indicated with the upper arrowhead. Lanes 16 (negative control), 17 cDNA 
from HEK293 with both NRD1 (lower strong band) and NRD2 (upper band, weak staining). 
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3.1.1 Production of NRD1- mutants 
For production of catalytically inactive NRD1 we aligned the sequences as shown in 
Fig. 3.3. The mutants published before were done in mouse NRD1 but not in the human NRD 
protein. These NRD mutants have either a point mutation in either the Zn2+-binding motif 
(HXXEH to HXXAH) or the catalytically important Cys948 (Cys to Ala) or a deletion of the 
DAC.  
 
Fig. 3.3 Alignment of NRD sequences of different species 
Alignment of (1) the human NRD sequence (Reference Sequence NM_002525.1) with (2) AY3602651 (homo 
sapiens nardilysin isoform (NRD1) mRNA, complete cds), (3) NM_012993 (Rattus norvegicus nardilysin1 
(Nrd1), mRNA), (4) X93208 (Rattus sp. mRNA for NRD2 convertase), (5) NM_146150 (Mus Muculus 
Nardilysin, N-arginine dibasic convertase, NRD convertase1 (Nrd1), mRNA), line (6) displays the consensus 
sequence. Due to space limitations, only the region comprising the DAC (marked in green) and the HFLEH-
motiv (marked light grey) are shown. Alignment was done using the online multi align tool (Corpet, 1988). 
 
 
All mutations were carried out here in the previously sequenced HsNRD1-pBSKII. The 
production of the ∆DAC mutant is illustrated in Fig. 3.4. Following the mutagenesis, the 
sequenced insert was cloned into pFastBacHtc or pcDNA6His-B, for expression in insect or 
mammalian cells. 
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5´aca gga aat aca aca gat gat gaa gaa ga ....... ttg gaa gaa tta gaa gag aga gca gaa ..
DACN T T R A E
5´aca gga aat aca acc ggt gat gaa gaa ga ....... ttg gaa gaa tta acc ggt aga gca gaa ..
DACN T T R A E
cc ggt gat gaa gaa ga ....... ttg gaa gaa tta a
DAC
5´aca gga aat aca ac c  ggt aga gca gaa ..
N T T R A EG
12
Point mutations: Restriction sites for Age I
Digestion with Age I
Religation:
 
Fig. 3.4 Scheme for the production of the ∆DAC deletion mutant of hsNRD1. 
Using site directed mutagenesis, we introduced point mutations into the hsNRD1 sequence to add a restriction 
site for AgeI. After digestion of the plasmid with AgeI and subsequent religation, the translation of the remaining 
sequence results in a replacement of the DAC with a single glycine residue, and links the protein sequence N- 
and C-terminal to the original DAC sequence.  
3.1.1.1 Recombination, transfection and protein expression of NRD with 
purification  
 
Fig. 3.5 Control of recombination of NRD-Bacmid-DNA 
A typical EtBR stained agarose gel with products from standard NRD PCR (see 2.2.15 for details) to control the 
successful recombination of NRD. The mix from several clones shown here in lane 1-4 was used to transfect Sf9 
cells. Lanes 1-4: hNRD1- FB1; -FB2-; FB5; - FB6, lane 5 H2O; lane 6 control (pBSKhsNRD1); for transfection 
in Sf9 cells the concentration was estimated from the agarose gel. 
 
The recombination of pFastBac-Htc-NRD (NRD1, NRD1, NRD1-mutants) with 
MaxEffiecency DH10 BacTM – cells, expression of NRD in Sf9 cells, followed by protein 
purification, were optimized for both NRD isoforms as well as for the NRD-mutants and are 
described in detail in materials and methods (see chapter 2.2.1.1.4 to 2.2.1.16 and 2.2.1.12). 
Tests on the optimal duration of Sf9-cells, transfected with working virus from any of the 
above mentioned constructs’ revealed that the harvest at 72 hours post transfection is optimal 
for the expression of the desired protein. 
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3.2  NRD as possible endopeptidase for p42IP4 
 
We here studied, whether the full-length metalloendopeptidase NRD might cleave 
p42IP4. Both proteins were incubated for 30 min up to 10 h. Only examples for one to four 
hours (Fig. 3.6) and 30 min (Fig. 3.7) are presented here. As shown by Western Blot in Fig. 
3.6 (A, B, C) there are no fragments of p42IP4 detectable albeit after longer incubation it 
appears that the intensity of the protein band appears weaker. This may result from ongoing 
precipitation of the protein, but is not critical for the general conclusion because the intensity 
of the protein bands in the control lanes (lane 5 and lane 10) is comparable in the lanes, which 
belong to the same incubation time (lanes 1-4 or lanes 6-9). 
Moreover, this decrease can be observed in all blots in Fig. 3.6, irrespective of the 
specific antibody used for detection of p42IP4. Western blots were done using specific 
antibodies directed against amino acids in the C-terminal, the N-terminal parts and amino 
acids in the central part of p42IP4. The antibody specificity is as indicated in the scheme above 
the blots in Fig. 3.6. Incubation of p42IP4 with NRD for 7 or 10 h under the same conditions 
and staining of the Western blots with the same antibodies  also revealed no fragments of 
p42IP4 (data not shown). 
To exclude fragments, which might not be detectable with our antibodies, we checked 
the possible cleavage of p42IP4 by NRD after incubation on a Coomassie-gel. In addition to 
the results from Western blotting, Coomassie staining (Fig. 3.7) also revealed no fragments of 
p42IP4 after incubation with NRD. 
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Fig. 3.6 NRD does not cleave p42IP4 after 1 or 4 h. Western Blot. 
p42IP4 (Sus scrofa) was tested as a substrate for NRD. Equimolar amounts (80 nM) of both proteins were 
incubated for 1 or 4 h. The reaction was stopped, samples were loaded onto a 12.5% SDS-PAGE. Western Blot 
was done using the following p42IP4-specific antibodies: A, # 1 (N-terminal part), and B, # 2 (central part). C, #3 
(directed against the C-terminal part). Antibody target amino acid residues are indicated in the p42IP4  protein 
scheme given on top. Lanes 5 and 10: control incubations; buffer was added instead of NRD. 
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Fig. 3.7 NRD does not cleave p42IP4 . Coomassie staining.  
p42IP4 (Sus scrofa) was tested as a substrate for NRD. 80 nM recombinant p42IP4 was incubated with 40 nM 
NRD for 15 min or 30 min in 20 mM potassium phosphate buffer, pH 7.0 (Csuhai E. et al 1998). The reaction 
was stopped by incubation at 90°C for 5 min. Samples were precipitated with methanol/acetone, dissolved in 
sample buffer and run on a 12.5% SDS-PAGE and stained with Coomassie dye.  
 
3.3 Modulation of peptidase-activity of NRD by p42IP4 
 
After we could demonstrate here that NRD does not cleave p42IP4, we were interested 
to verify whether p42IP4 instead influences the enzymatic activity of NRD. We performed a 
kinetic assay using the substrate Abz-GGGFLRRVGQ-EDDnp. In this substrate, the 
fluorescence of the N-terminal Abz-group is masked by the quenching effect of the Dnp-
group. After cleavage of the peptide bonds, this quenching effect is abrogated and the 
fluorescence of the Abz-group can be detected. 
As shown in Fig. 3.8A, p42IP4 positively modulates the enzymatic activity of NRD by 
shifting the reaction curve to the left side and increasing the slope of the reaction curve. 
Addition of p42IP4 increases the reaction by approximately 12% after 5 min and 25% after 20 
min. Experiments using recombinant human NRD, lacking the DAC showed no reaction (data 
not shown here). Because p42IP4 binds to the DAC of NRD, we were interested to see whether 
this potentiation of enzyme activity depends on the equimolar ratio. As shown in Fig. 3.8, 
there are no differences for the enzyme kinetics with equimolar, two-fold and 0.5 ratio of 
p42IP4 and NRD. To further confirm that p42IP4 is indeed a modulator of NRD and not a 
substrate, the samples of experiment 3.8. A were analyzed by Western Blot. As shown in Fig. 
3.8B, there are no fragments of p42IP4 detectable. Moreover, lanes 5-8, which correspond to 
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the curves in Fig. 3.8A (same symbols in curves and Western Blot) show the increasing 
amounts of p42IP4 (lane 6: 40 nM, lane 7: 80 nM, lane 8: 160 nM). Additionally, comparison 
of lane 4 and 7 shows identical signal strength. This supports the idea that p42IP4 and the 
peptide substrate Abz-GGGFLRRVGQ-EDDnp do not compete for the active site of NRD. 
 
Fig. 3.8 p42IP4 enhances the enzymatic activity of NRD. 
A. Enzymatic activity of NRD in the presence of p42IP4. Fluorescence measurement using 1 µM of the quenched 
substrate Abz-GGGFLRRVGQ-EDDnp (bovine adrenal medulla peptide; (Csuhai et al., 1999b). Mean values 
and error bars for SEM; RFU = relative fluorescence units. Medium lowess curve fitting was done using 
GraphPad Prism. Data are from five experiments, performed in triplicate. B. p42IP4 is not a substrate for NRD1 
and does not compete with substrate for the active site of the enzyme. B: Western Blot. After fluorescence 
measurement (time of incubation 30 min; see above) using the peptide substrate Abz-GGGFLRRVGQ-EDDnp, 
the different samples of the enzyme kinetic experiment (see Fig. A), were run on a 12.5% SDS-gel for Western 
Blot using the p42IP4 antibody 117-2. Lanes 5-8 correspond to measurements shown in Fig. 3.8 A. p42IP4 does 
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not compete with Abz-GGGFLRRVGQ-EDDnp for the active site of the enzyme because the signals in lanes 4 
and 7 are equal.  
 
3.4 Expression of NRD and p42IP4 in SH-SY5Y cells 
 
To investigate the relevance of the interaction between p42IP4 and NRD in vivo, we 
used SH-SY5Y cells. These cells represent a neuroblastoma cell line, which was originally 
derived from the cell line SK-N-SH (Biedler et al., 1978). Moreover, these cells can be used 
as a model system for investigations of processes in neurons. SH-SY5Y can be differentiated 
into a neuronal-like cell type when exposed to low concentrations of RA like many other 
neuroblastoma cell lines (Pahlman et al., 1984). 
It is important to consider that this cell line consists of two phenotypes of cells with a 
majority of neuroblast-like cells, which display different behavior after treatment with RA 
(Preis et al., 1988). Upon stimulation with RA, 25% of the cells grow extensions longer than 
50 µm but at the same time, the non-neuronal phenotype increases dramatically and 
overgrows the culture dish. Additionally, many gene products used as control for 
normalization of gene expression are also subject to changes after RA treatment. For example, 
the ratio of actin expression to total protein expression was significantly increased in cells 
differentiated with RA (Asada et al., 1994). 
These SH-SHSY5Y cells were used as a model system to investigate the role of the 
proteins p42IP4 and NRD during differentiation. Moreover, we studied the localization of both 
proteins in the SH-SY5Y cells. 
3.5 Expression of p42IP4 and NRD in SH-SY5Y cells after RA-treatment 
3.5.1 Upregulation of NRD2 on mRNA-level after RA stimulation 
 
Semi-quantitative RT-PCR showed that p42IP4 and both isoforms of NRD are 
expressed in SH-SY5Y cells on mRNA-level (Fig. 3.9, normalized to day 0). After 
stimulation with 10 µM RA the mRNA level of NRD2 is upregulated after 3 days and stays at 
this elevated level for 15 days. Interestingly, after several days of RA treatment the mRNA-
level of NRD1 appears not to be changed at all. In contrast to that, the p42IP4 mRNA level is 
not upregulated, even more, a down-regulation of approximately 25% by day 6 and by 50% at 
day 15 could be observed. Interestingly, at day 15 NRD2 is upregulated together with a 
concomitant reduction of p42IP4, which is significant and becomes noticeable already at day 6 
of RA stimulation. 
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Fig. 3.9 Change in mRNA - and protein expression in SH-SY5Y cells after retinoic acid (RA) treatment.  
SH-SY5Y cells were exposed to RA (10 µM) for 3, 6, 9, 12, or 15 days. Medium containing 10 µM RA was 
changed every 3 days. Then cells were harvested. A. RNA was isolated and RT-PCR was done using specific 
primers for p42IP4, and primers for NRD. PCR products were quantified (Biorad Quantitiy One). B. Cells were 
lysed, precipitated with methanol/acetone 1:1 loaded onto a 10% (for p42IP4) or 5% (NRD) SDS-polyacrylamide 
gel. Blots were scanned and quantified (Biorad Quantitiy One). Blots were stained for NRD using the N20 
antibody (polyclonal goat, Santa Cruz Biotechnology). Data are expressed as mean ± SE from 4 – 5 experiments. 
Statistical analysis, * p<0.05, ** p<0.01 compared to day 0. Error bars indicate Standard Error. C. Typical blots 
showing NRD, tubulin and GAPDH staining.  
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3.5.2 Upregulation of NRD on protein level after RA stimulation 
 
As demonstrated above, the mRNA-levels of both NRD1 and NRD2 are not equally 
expressed after stimulation with RA. Therefore, we were interested to investigate whether the 
protein expression of both isoforms displays a similar regulation. To improve the resolution of 
the different protein bands of the two NRD isoforms, which by differ only about ~ 5 kDa, 
protein samples were loaded on 5% polyacrylamide gels to enhance the electrophoretic 
separation. 
However, contrary to the findings on mRNA level, we were not able to detect any 
upregulated NRD2 protein (not shown in Fig. 3.9). We can exclude that this is caused by the 
use of the NRD antibody, because this antibody is able to detect recombinant NRD2 protein, 
cloned from HEK293 cells. The Western blot for recombinant NRD2 is not shown here. 
Nevertheless, we were able to detect a strong upregulation of the NRD1 protein, which 
was highly significant after 15 days of RA treatment.  
Staining with antibodies against p42IP4 revealed that p42IP4 is not expressed as protein 
in detectable amounts in SH-SY5Y cells. Treatment of the SH-SY5Y cells with RA did not 
induce a protein expression of p42IP4. 
 
3.5.3 NRD is expressed in the neurites of stimulated SH-SY5Y cells 
 
Since we could show an upregulation of NRD in SH-SY5Y cells stimulated with 10 
µM RA, we were interested in the cellular localization of NRD and p42IP4.  
Treatment of SH-SY5Y cells with RA induces morphological changes in these cells. 
Compared to untreated cells they appear in a lengthened shape and start to develope neurites 
followed by establishing neural networks in the culture dish. This can be observed from day 
three onwards in the cell culture (see also Fig. 3.10 panel B). Moreover, the network of the 
neurites is more prominent over the time course of our experiments. This is visible from day 6 
until day 15 (Fig. 3.10 B-F middle panel), but the network is fully developed between day 9 
and day 12 (Fig. 3.10 D and E, middle panel). 
Using confocal microscopy, we found that NRD is located in the cytosol and in the 
growing neurites of the stimulated SH-SY5Y cells, as indicated by arrowheads in Fig. 3.10 D-
F, right panel. Interestingly, after 6 days RA treatment (Fig. 3.10 C), NRD appears to be 
located within vesicular structures, which are even more visible after day 9 of RA-treatment 
(Fig. 3.10 D). As shown before by Western blot, staining with antibodies against p42IP4 could 
not detect an expression of this protein. This finding proves that SH-SY5Y cells are optimal 
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for analyzing the cellular consequences of p42IP4 after stable transfection of GFP-tagged 
p42IP4 into neural cells. 
 
 
Fig. 3.10 Expression of NRD in SH-SY5Y cells after retinoic acid (RA) stimulation. 
NRD is expressed in neurites and vesicular structures (arrowheads). SH-SY5Y cells were exposed to RA (10 
µM) for 3 (B), 6 (C), 9 (D), 12 (E), or 15 (F) days. Control SH-SY5Y cells were maintained in DMEM 
supplemented with 15% FCS. Medium, containing 10 µM RA was changed every 3 days. Cells were fixed at the 
indicated time points, and immunohistochemistry was done using the antibodies N20 for NRD and Alexa Fluor 
488 anti goat for detection. The white bar in the left and middle panels indicates 20 µm. 
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3.5.4 Influence of stable transfection of GFP-tagged p42IP4 on NRD expression 
 
We did not observe an expression of p42IP4 on protein level in SH-SY5Y cells and, 
therefore, we decided to use this cell line to verify, whether p42IP4 can influence the RA-
induced upregulation of NRD on the protein level. 
We stably transfected SH-SY5Y cells with GFP-p42IP4 and stimulated the transfected 
cells with 10 µM RA with the same protocol as before in untransfected SH-SY5Y cells. As 
shown in Fig. 3.11, NRD is not upregulated after 15 days. Surprisingly, the upregulation, 
albeit at a lower level, appears at an earlier time point. This indicates a shift of the 
upregulation from day 15 to day 6 compared to untransfected SH-SY5Y, treated with RA. 
Additionally, to exclude any influences of the GFP-tag, SH-SY5Y cells were stably 
transfected with pEGFP-C1-empty vector and stimulated as described before for SH-SY5Y 
and SH-SY5Y-p42IP4 cells. As demonstrated in Fig. 3.12, NRD is not upregulated after 6 days 
in SH-SY5Y-GFP cells, which gives evidence for a similar behavior of GFP-transfected cells 
and untransfected SH-SY5Y cells. 
It is important to note that the down regulation of NRD in p42IP4-transfected cells, 
observed at later time points is not caused by p42IP4. Most probably, the protein expression 
after day 6 is influenced by the GFP-tag, as the NRD expression at day 9 and progressing 
until day 15 is comparable to cells transfected with p42IP4 or GFP-only (comparison Fig. 3.9, 
Fig. 3.11, Fig. 3.12). 
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Fig. 3.11 Change in protein expression in SH-SY5Y cells, stably transfected with p42IP4 after retinoic acid 
(RA) treatment. 
SH-SY5Y-p42IP4 cells, stably transfected with GFP-tagged p42IP4 were exposed to RA (10 µM) for 3, 6, 9, 12, or 
15 days. Medium containing RA was changed every 3 days. Cells were harvested at the incubation points 
mentioned and lysates were analyzed by Western Blot for the presence of NRD, as described in Fig. 3.9. 
 
 
Fig. 3.12 Change in protein expression in SH-SY5Y-GFP-only cells after retinoic acid (RA) treatment. 
SH-SY5Y-GFP-only cells, stably transfected with GFP-only were exposed to 10 µM RA for 3, 6, 9, 12, or 15 
days. Medium containing RA (10 µM) was changed every 3 days. Cells were harvested and lysates were treated 
as described in Fig. 3.9. Error bars indicate Standard Error; Data are from four independent experiments with 
each treatment performed in triplicate.  
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3.5.5 Localization of p42IP4 and NRD in p42IP4-transfected SH-SY5Y cells 
 
 We further elucidated the interaction between p42IP4, NRD, and tubulin. For that 
purpose cells were analyzed by confocal microscopy. For this, SH-SY5Y-p42IP4 cells, stably 
expressing p42IP4-GFP, were seeded on cover glasses, fixed and permeabilized for 
immuncytochemistry. Confocal imaging revealed the co-localization of p42IP4, NRD, and β- 
tubulin in the cytosol and at the plasma membrane (light–pink staining) (merged picture in 
Fig. 3.13a and histogram in Fig. 3.13b). This colocalization is clearly visible in the 
histograms, where the peaks overlap as seen in the region from 25 µm to 45 µm from start of 
the arrow. This is seen for all three curves as marked by tick lines on the arrow in the merged 
picture and in the histogram in Fig. 3.13a and Fig. 3.13b.  
Contrary to tubulin and NRD, p42IP4 is also localized in the nucleus. The 
colocalization of NRD alone with β-tubulin was published before (Ma et al., 2005) and we 
previously found an interaction of p42IP4 with α-tubulin (Galvita et al., 2009).  
Therefore, we were interested to find out, whether the interaction of both proteins with 
tubulin might have an impact on the interaction between p42IP4 and NRD. For this, we 
decided to verify whether changes in the tubulin-cytoskeleton would affect the binding of 
NRD and p42IP4. 
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Fig. 3.13 Colocalization of NRD, p42IP4 and tubulin in SH-SY5Y-p42IP4 cells. 
SH-SY5Y cells, stably expressing p42IP4-GFP, were seeded on cover glasses, fixed and permeabilized for 
immuncytochemistry. Cells were double stained with NRD and β-tubulin antibodies and with Alexa Fluor 555 
followed by Alexa Fluor 633 antiserum, as described in Materials and methods (see chapter 2.2.4). (a) Confocal 
imaging of p42IP4-GFP (green; left upper panel), β-tubulin (blue; in left lower panel) and NRD (red; in right 
upper panel). The merged picture (right lower panel) illustrates the co-localization of p42IP4, NRD, and β- 
tubulin in the cytosol and at the plasma membrane (light–pink staining). Pictures shown are representative of at 
least three independent experiments. (b) Histograms represent the fluorescence intensity distribution determined 
for a cross-section of the cell, as indicated by the white arrow in (a), which corresponds to the black arrow in (b). 
Curves show smoothened data, which were calculated from average values of neighboring points. The peaks 
overlap for all three curves in an area marked by tick lines on the arrow (25 µm to 45 µm from start of the 
arrow), indicating co-localization of p42IP4, NRD and β-tubulin in SH-SY5Y cells, transfected with p42IP4-GFP.  
 
 
Results 
 67 
For this purpose, we used nocodazole, known to be a potent inhibitor of tubulin 
polymerization, to check if the colocalization of p42IP4 and NRD is changed. To increase the 
protein expression of NRD we stimulated the cells with 10 µM RA for 6 days prior to 
nocodazole treatment. Preliminary experiments showed that p42-GFP transfected cells, pre-
treated with 10 µM RA for 6 days, detached from the cell culture dish when incubated with 5 
µM nocodazole for 1.5 –4 h. We therefore treated stably transfected p42IP4-GFP and GFP-
only cells with 5 µM nocodazole for only 1 h. Interestingly, the detaching could not be 
observed in cells transfected with GFP-only. 
 
Fig. 3.14 Influence of treatment of SH-SY5Y-p42IP4 cells with nocodazole on localization of NRD, p42IP4 
and tubulin. 
SH-SY5Y cells, stably transfected with p42IP4-GFP (or control cells, transfected with empty GFP-vector), were 
seeded on cover glasses and treated with 10 µM retinoic acid (RA) for 6 days, washed and treated with 5 µM 
nocodazole for 1 h at 37°C before they were fixed and permeabilized for immuncytochemistry. Cells were 
double stained with NRD and β-tubulin antibodies and with Alexa Fluor 555, followed by Alexa Fluor 633 
antiserum, as described in Materials and Methods. (a) Treatment of p42IP4-GFP transfected cells: Confocal 
imaging of co-localization of p42IP4-GFP (green), β-tubulin (blue) and NRD (red). The merged picture and the 
curves for fluorescence intensity distribution demonstrate that treatment with nocodazole caused a co-
localization of p42IP4 and tubulin (overlapping intensity peaks), whereas a co-localization of all three proteins is 
visible only at vesicular structures (indicated by asterisks). (b) Treatment of control cells (GFP-transfected SH-
SY5Y cells). Confocal imaging of the localization of GFP, β-tubulin (blue), and NRD (red). The merged picture 
and the curves for fluorescence intensity distribution show that there are no specific overlapping peaks for the 
distribution of the three proteins: GFP is almost evenly distributed, NRD is weakly expressed, and tubulin has a 
similar distribution like in cells not treated with nocodazole (see Fig. 3.13). All curves show smoothened data, 
which were calculated from average values of neighboring points. 
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As indicated by the overlapping intensity peaks in Fig 3.14a, treatment with 
nocodazole causes a redistribution of p42IP4 and tubulin, but does not alter their 
colocalization. A colocalization of all three proteins is only visible in vesicular structures, 
which occur at the peaks at 11, 18 and 26 µm distance. Comparison of the SH-SY5Y-p42IP4 
with (Fig. 3.14a) or without nocodazole treatment (Fig. 3.13), clearly shows the influence of 
nocodazole on the distribution of all three proteins in the cells.  
Without nocodazole treatment, p42IP4 is located in the nucleus, cytosol and at the 
plasma membrane. Moreover, p42IP4 appears to be colocalized with tubulin and NRD in the 
cytosol and at the plasma membrane in, where it is more evenly expressed (Fig. 3.13 region, 
indicated by the tick lines on the arrow starting at 25 µm). After treatment, the colocalization 
of p42IP4 and tubulin remains throughout the cytoplasm and at the membrane, albeit the 
distribution of both proteins resembles a punctuated pattern. This leads to regions with high 
occurance of both proteins (Fig. 3.14a peaks at 0 µm and at ~5 µm distance) and other regions 
in the cell, which show a low intensity for both proteins (intensity below 50 at 2.5 µm and 15 
µm in Fig. 3.14).  
SH-SY5Y-GFP cells, which were used as control did not show such comparable 
specific peaks in their protein distribution after nocodazole treatment (Fig. 3.14b). Similar to 
cells, which were not treated with nocodazole, these cells show an almost even distribution of 
GFP fluorescence and the same distribution of tubulin.  
It is important to note that the stimulation of the cells, presented in Fig. 3.13 and 3.14 
with RA for 6 days, was done solely to enhance the expression of NRD. It is possible to detect 
NRD in SH-SY5Y cells without RA treatment (see also Fig. 3.10, left panel), but compared to 
the expression of tubulin and the overexpression of GFP-p42IP4 or GFP alone, the levels of 
NRD are rather low. This low NRD expression makes it difficult to investigate the 
colocalization of the three proteins and their changes after nocodazole treatment. 
Investigations concerning the influence of p42IP4 on NRD expression revealed an upregulation 
of the metalloendopeptidase after 6 days (see Western blots shown in Fig. 3.11). Therefore, 
the different intensities in NRD expression in SH-SY5Y-p42IP4 cells compared to SH-SY5Y-
GFP cells, displayed in the graphs in Fig. 3.14 confirm this on cellular level. Compared to 
p42IP4-expressing cells, NRD is weakly expressed in the GFP-only expressing cells after 6 
days of RA treatment, which is in agreement with our findings shown before (see chapter 
3.5.4 for reference).  
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3.5.6 Altered response to nocodazole treatment in p42IP4 expressing SH-SY5Y 
cells 
 Due to the remarkable differences observed in the p42IP4 transfected versus control 
cells, we estimated the number of cells with such structural changes, which are indicated by 
arrows in the example of SH-SY5Y-p42IP4-GFP cells shown in the inset picture in Fig. 3.15. 
For this purpose, within all GFP-only and GFP-p42IP4-transfected cells, we counted the cells, 
which showed these characteristic differences in their distribution of GFP, like accumulation 
in vesicles, or uneven distribution in parts of the cell with surrounding cellular areas devoid of 
any GFP-fluorescence. 
Counting of the number of cells (Fig. 3.15) revealed that both p42IP4-GFP as well as 
GFP control cells, which received a treatment of RA or nocodazole alone, have a basal level 
of cells with these structural changes. This number of affected cells corresponds to 
approximately 20% of the total cell number in these cells. 
Only treatment of SH-SY5Y-p42IP4 cells with RA and subsequent treatment with 
nocodazole caused a dramatic increase in the number of cells showing signs of structural 
changes. On the contrary, control cells did not display such increased structural changes after 
the same treatment. The number of cells with structural changes remained at the same low 
level, similar to single RA or nocodazole treated control cells. 
 
Fig. 3.15 Structural changes in SH-SY5Y-GFP and SH-SY5Y-p42IP4 cells treated with nocodazole.  
SH-SY5Y cells, stably transfected with p42IP4-GFP (or control cells, transfected with empty GFP-vector), were 
seeded on cover glasses, treated with 10 µM retinoic acid (RA) alone for 6 days or treated with 5 µM nocodazole 
only for 1 h at 37°C, or treated with 10 µM RA for 6 days followed by 5 µM nocodazole treatment for 1 h at 
37°C before they were fixed. We counted the cells with structural changes. Arrows (inset picture) indicate 
examples for cells with structural changes. We calculated the ratio of cells with structural changes to the total 
number of transfected cells, transfected with GFP-p42IP4 or GFP-only, which is displayed in the graph. Data was 
analyzed by an unpaired Student t-test, with ** p<0.01 considered to be significant. Results are from four 
independent experiments, in which four independent areas for each treatment were analyzed. 
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3.6 In vitro experiments to verify the interaction of NRD and p42IP4 
3.6.1 Pulldown experiments with recombinant NRD and p42IP4  
An interaction of NRD with p42IP4 could not be found using pulldown experiments 
with recombinant GST-p42IP4 together with recombinant human NRD (wt, ∆DAC, point 
mutants Cys C948A and HFLAH). We therefore assumed that the interaction between both 
proteins is weak. Alternatively, given the many interaction partners of both proteins we 
hypothesized that another protein may modulate the interaction. 
3.6.2 Tubulin enhances the interaction of NRD1 with p42IP4 
To further investigate the interaction between NRD, p42IP4 and tubulin, we performed 
Far western blots. Far western blot is helpful to determine whether two proteins interact 
directly or whether a third protein mediates the physical interaction between both proteins 
(Wu et al., 2007). 
For this purpose, we prepared Western Blot strips, containing 500 ng of recombinant 
p42IP4 and added recombinant NRD1 and polymerized tubulin to the blots, as described in 
materials and methods (see chapter 2.2.3.10). Firstly, to optimize the experimental conditions, 
we tried different concentrations of tubulin, ranging from 0.1 to 10 µg per reaction in a total 
volume of 1.25 ml. For normalizing the data, we set the binding of NRD to p42IP4 without 
addition of tubulin to 1 (Fig. 3.16 first bar chart in a, b and c). 
Quantification of the blots showed that an amount of 0.1 µg of tubulin is sufficient to 
significantly increase the binding of hsNRD1 to p42IP4 (Fig. 3.16a). Furthermore, increasing 
the amount of tubulin in 10-fold steps shows that the relative binding of NRD to p42IP4 
reaches a plateau level at 2.5 fold binding ratio, as compared to the blots without addition of 
tubulin. For the following experiments, we used the 10 µg tubulin per assay, because with this 
amount the detectable signal, as compared to background, was optimal both for visibility and 
signal strength (also Fig. 3.16a). 
We were then interested to find out whether the interaction of NRD and p42IP4 is also 
enhanced, when tubulin is not polymerized prior to the incubation with NRD and application 
to p42IP4. Quantification of the Far Western blots using nonpolymerized tubulin, shows that 
the addition of nonpolymerized tubulin does not significantly increase the relative binding of 
NRD1 to p42IP4 (Fig. 3.16b). The mean value was 1.5 ± 0.5 binding ratio which is not 
significant compared to the binding of NRD to p42IP4 without the addition of tubulin. 
For polymerized tubulin on the contrary, the binding was clearly significantly 
enhanced with a mean value of 2.3 ± 0.4 binding ratio. 
Results 
 71 
 
Fig. 3.16 Far-Western Blots to study the influence of tubulin on binding of NRD to p42IP4.  
For Western Blots we used 500 ng of recombinant p42IP4 protein (lanes 1, 3, 5, 7) or 500 ng of BSA (lanes 2, 4, 
6, 8) for control. Lanes 1 and 2 are without addition of tubulin. The proteins were separated on a 10% SDS gel 
and blotted onto a nitrocellulose membrane. Far-Western Blots were done following a protocol described before 
(Wu et al., 2007) with modifications explained in Materials and Methods. (a) Influence of the concentration of 
polymerized tubulin on the binding of NRD to p42IP4, testing 0.1, 1, and 10 µg tubulin per assay. The binding of 
NRD to p42IP4 without addition of tubulin corresponds to the ratio 1. (b) Influence of the polymerization status 
of tubulin on binding of NRD to p42IP4. Experiments were performed as described in Materials and Methods, 
using 10 µg of non-polymerized or polymerized tubulin. The binding of NRD to p42IP4 without addition of 
tubulin corresponds to the ratio 1. (c) Influence of D-Ins(1,3,4,5)P4 (lanes 3 and 4) and L-Ins(1,3,4,5)P4 (lanes 5 
and 6) on the binding of NRD to p42IP4 without the addition of tubulin. The binding of NRD to p42IP4 without 
the addition of D-Ins(1,3,4,5)P4 or L-Ins(1,3,4,5)P4 (lane 1) was used as control (ratio=1). We performed an 
unpaired Student-t-test with * p<0.05 and ** p<0.01 considered to be significant compared to control, with at 
least 4 (a), 6 (b) or 3 (c) independent experiments; n.s. not significant. 
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To prove that the binding of NRD to p42IP4 occurs with a functionally renatured of 
p42IP4 protein on the membrane, we performed Far-Western Blot experiments in the presence 
of both enantiomers of the soluble ligand of p42IP4 Ins(1,3,4,5)P4. 
D-Ins(1,3,4,5)P4 is the effective ligand for p42IP4 whereas L-Ins(1,3,4,5)P4 binds only 
weakly (Hanck et al., 1999). When incubated with p42IP4 and NRD, D-Ins(1,3,4,5)P4 forces 
the dissociation of both proteins. However, the enantiomer L-Ins(1,3,4,5)P4 is a very poor 
ligand for p42IP4 and has no influence on the interaction of NRD with p42IP4 (Stricker et al., 
2006).  
Therefore, the addition of the enantiomers to the membranes should result in a 
difference in the binding of NRD to p42IP4 if it is renatured. As shown in Fig. 3.16c, there is a 
significant difference between the binding of NRD to p42IP4 in the presence of either the D-
Ins(1,3,4,5)P4 or L-Ins(1,3,4,5)P4. These results are consistent with protein binding 
experiments which were published before (Stricker et al., 2006). The binding of NRD to 
p42IP4 on the blots in the presence of the D-Ins(1,3,4,5)P4 was decreased as compared to 
control conditions. As expected, in the presence of the low affinity ligand L-Ins(1,3,4,5)P4, the 
binding of p42IP4 and NRD was not affected.  
Moreover, the Far-Western Blot experiments presented in Fig. 3.16 show that the loss 
of interaction of NRD, p42IP4 and tubulin observed in SH-SY5Y-p42IP4 cells after nocodazole 
treatment has a biochemical basis.  
 
3.6.3 Influence of NRD-mutants on binding to p42IP4 
 
  Previous experiments from our group showed that p42IP4 can interact with NRD from 
rat brain lysate (Stricker et al., 2006). Moreover, interaction studies performed with p42IP4 and 
a recombinant DAC, from mouse or rat or human or combinations thereof, demonstrated that 
this domain of NRD is sufficient for interaction. Additionally it was confirmed that the 
interaction can be regulated via ligands of NRD and p42IP4 respectively (Stricker et al., 2006). 
As explained in detail in 3.3, p42IP4 can influence the catalytic activity of full length NRD. 
We were therefore interested, whether NRD-mutants, lacking important catalytic sites, have 
any differences in their binding properties with p42IP4. 
Furthermore, we wanted to verify, whether an addition of tubulin has the same effect 
on the binding of the mutants to p42IP4, as on the wild type NRD. For this purpose, we 
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produced NRD mutants, as described in 3.1.1 and performed Far Western blot, without or 
with the addition of tubulin, as done before with NRD1. 
Quantification of the blots (Fig. 3.17) showed that without the addition of tubulin wild 
type NRD1 and the NRD1-mutants show no differences in their interaction with p42IP4. The 
catalytically inactive mutant of NRD, with a replacement of the glutamate in the HFLEH 
motif by an alanine, also showed increased binding to p42IP4 in the presence of tubulin, 
comparable to wt NRD.  
Interestingly, the interaction of p42IP4 with the NRD-mutant C948A, where the proposed 
catalytically important cysteine was replaced with alanine, displayed no differences in binding 
to p42IP4 irrespective of the presence or absence of tubulin. 
The mutant of NRD, lacking the acidic domain (DAC) is able to bind p42IP4. Addition of 
tubulin does not enhance the binding of NRD-∆DAC to p42IP4. This gives evidence that 
p42IP4 binds not exclusively to the DAC and an interaction with NRD is possible even without 
this domain. Moreover, the DAC of NRD seems to be involved in the binding of tubulin 
during the interaction of NRD, tubulin, and p42IP4. Additionally, the structure of NRD seems 
to be important for the selectivity of the potentiating effect of tubulin on the interaction of 
NRD, p42IP4.  
 
Fig. 3.17 Binding of NRD mutants to p42IP4 in the absence or presence of tubulin. Far-Western Blots 
To study the influence of tubulin on the binding of NRD mutants to p42IP4 we produced wild type NRD and the 
NRD-mutants NRD-HFLAH, NRD-∆DAC or NRD-C948A, as described in chapter 3.1 and performed Far-
Western Blot, without or with the addition of polymerized tubulin as described in legend to Fig. 3.16. Blots in 
the lower panel show examples for the binding of NRD or NRD mutants to p42IP4 without (1) and with (2) 
polymerized tubulin; the control lane (BSA, similar to Fig. 3.16) is not shown here. The binding of NRD to 
p42IP4 without addition of tubulin was set as ratio 1. We performed an unpaired Student-t-test with * p<0.05 
considered to be significant with at least 5 independent experiments. 
 
Results 
 74 
3.6.4 Influence of p42IP4 on sAPPα-levels and Aβ-40 production in SH-SY5Y 
cells 
 
It was shown that NRD can influence the production of sAPPα via TACE activation 
(Hiraoka et al., 2007). Moreover, treatment of SH-SY5Y cells with RA upregulates the 
release of sAPPα after 6 days (Holback et al., 2005). Therefore, we wanted to clarify whether 
the upregulation of NRD on day 6 in SH-SY5Y cells overexpressing p42IP4 (Fig. 3.11), results 
in an enhanced release of sAPPα into the culture medium. Such an increased release of sAPPα 
would prove an indirect influence of p42IP4 on the shedding of APP. 
For detection of sAPPα release we used SH-SY5Y, SH-SY5Y-GFP and SH-SY5Y-
p42IP4 cells, which were stimulated with 10 µM RA for 0, 3 or 6 days, to clarify whether the 
before mentioned upregulation of NRD on day 6 influences the release of sAPPα into the cell 
medium. 
For detection of sAPPα we performed Western blots using the specific antibody 6E10. 
This antibody was shown to bind specifically to released sAPPα but can also detect 
membrane bound APP and Aβ. All experiments were carried out four times, each time in 
triplicate for both cell lysates and for the precipitated supernatant (the serum-free culture 
medium) from the respective culture. 
Under our experimental conditions, neither in transfected SH-SY5Y nor in wt cells it 
was possible to get consistent results for sAPPα-release. Therefore, the data were not suitable 
for statistical evaluation and the Western blots of these of these experiments are not shown 
here. 
The protein p42IP4 was found to be localized in AD-plaques and to interact with 
RanBPM, a protein influencing the APP-shedding via BACE1. Therefore, we investigated 
whether instead of promoting the APP cleavage via NRD and α-secretases p42IP4 influences 
the cleavage of APP via BACE1. For this, we investigated the effects of p42IP4 on the Aβ-40 
release in SH-SY5Y cells, and SH-SY5Y cells transfected with p42IP4 or GFP-only. An Aβ-40 
sandwich ELISA was used to measure the peptide released into the culture medium.  
Incubation of the cells for 4 h and kept under serum-free conditions without RA-
treatment and even increasing the incubation time to 18 h did not reveal any Aβ-40 release at 
all. Only after 6 days of serum-free incubation, we were able to detect a basal release of Aβ-
40 into the culture media. Moreover, the difference in Aβ-40 release among the different cell 
types was not statistically significant (Fig. 3.18). There seems to be a tendency for the cells 
transfected with the GFP-tagged protein (p42IP4-GFP and GFP-only) to have an increased Aβ-
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40-release. Nevertheless, only the range of Aβ-40 release in GFP-only cells is wider than in 
GFP-p42IP4. 
 
Fig. 3.18 Aβ-40-release from control and transfected SH-SY5Y cells. 
For detection of released Aβ-40, SH-SH5Y cells, and SH-SH5Y-GFP cells, SH-SH5Y-p42IP4 cells were grown 
in serum-free media for 6 days without RA-treatment. The complete cell culture medium from each well was 
precipitated with trichloroacetic acid and dissolved in 50 µl of sample diluent of the Aβ40-ELISA-kit (hAmyloid 
β40 ELISA (HS), the GENETICS company, Schlieren Switzerland). The test was started immediately according 
to the manufacturer’s instructions. Data presented here are from four independent experiments with each 
treatment performed in triplicate. We performed an unpaired Student-t-test with p<0.05 considered to be 
significant.  
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4  Discussion 
 
The study presented here focused on the characterization of the interaction of p42IP4 with 
Nardilysin (NRD) on the molecular level, the modification of the interaction through a third 
interaction partner and the role of the protein-protein interaction for neurodegenerative and 
developmental processes and differentiation. 
p42IP4 is a 42 kDa Arf-GAP protein, which is mainly expressed in neurons. Recently it 
was renamed ADAP1 for a consensus nomenclature (Kahn et al., 2008). It was demonstrated 
that p42IP4 interacts with a variety of proteins, which places this protein at an interesting 
position in various physiological processes in the cell, ranging from tissue regeneration, 
transport of vesicles to involvement in mitochondrial Ca2+ signaling. A clear functional role 
of p42IP4 has yet to be established. Therefore, the knowledge gained from investigations of 
individual interactions should help to define the functional role of p42IP4 in the cell. 
It was published before that NRD and p42IP4 are involved in neurodegenerative diseases. 
p42IP4 was found to be colocalized in plaques of AD brains (Reiser and Bernstein, 2002). 
NRD was shown to be involved in myelination processes and axonal maturation (Ohno et al., 
2009). 
Moreover, it was demonstrated before that p42IP4 is able to modulate dendritic 
differentiation, to bind to actin and thereby modulate the neuronal actin cytoskeleton (Moore 
et al., 2007) (Thacker et al., 2004). Additionally, it was shown for p42IP4 as well as for NRD 
that they can bind to tubulin, albeit to different subunits (Galvita et al., 2009) (Ma et al., 
2005). Previous investigations in our laboratory revealed that p42IP4 can interact with the 
domain of NRD, which is proposed to be important for regulation of the enzymatic activity 
(Stricker et al., 2006).  
4.1 NRD does not cleave p42IP4 
 
NRD belongs to the inverzincin/M16-family of metalloendopeptidases (reviewed in 
(Hospital and Prat, 2004), a family with members that can act bifunctionally as a protease and 
through a non-enzymatic behavior. 
We previously showed (Stricker et al., 2006) that the interaction of full length p42IP4 
protein and the acidic domain (DAC) of NRD can be regulated by ligands of each of the 
interacting proteins. Therefore, we here investigated, whether the full-length 
metalloendopeptidase is able to cleave p42IP4. 
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Fig. 4.1 Putative cleavage sites for NRD in the p42IP4 amino acid sequence. 
Pairs of doublets of basic amino acids are indicated with (A) solely arginine residues (purple), (B) doublets of 
arginine and lysine residues (red), or arginine alone (purple). In (C) single arginine residues (green) are marked 
in addition to doublets as indicated in (A) and (B) 
 
We could show that NRD does not act as a protease on p42IP4 although the protein 
sequence of p42IP4 contains several cleavage sites. As shown in Fig. 4.1 (A), p42IP4 contains 
two doublets of Arg within the protein sequence.The first cleavage could be within the 
nuclear localization signal (MAKERRRAV) (Tanaka et al., 1999) and a second Arg-Arg site 
is at position 280-281. Cleavage at these sites would be clearly detectable with our cleavage 
assay, because it would result in a 30 kDa and a 10 kDa fragment of p42IP4. Furthermore, 
NRD was shown to cleave at pairs of basic amino acid residues, which do not solely contain 
Arg residues (Chesneau et al., 1994). These additional putative cleavage sites are marked in 
Fig 4.1 (B). Proteolysis at all of these sites would cause small peptides (14.3 kDa, 1.1 kDa, 
13.2 kDa, 0.9 kDa, 5.5 kDa and 4.4 kDa) and result in a smear of bands, which we did not 
observe. Furthermore, experiments with a short time incubation (30 min) indicate that the 
total amount of full-length p42IP4 does not change. Also long time cleavage assays (4 or 12 h) 
showed no reduced amount of p42IP4. 
Additionally, it is known that NRD is able to cleave at single basic amino acid residues 
(Chow et al., 2003), albeit with much lower efficiency. In Fig. 4.1 (C) the putative cleavages 
sites with single Arg residues are indicated (green). Single lysine residues are not shown in 
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Fig. 4.1 (C). Cleavage at those sites is not detectable with our methods. Further biochemical 
methods like mass spectrometry would be necessary to detect such small fragments.  
In summary, we can most likely exclude cleavage of p42IP4 by NRD. Since NRD 
belongs to a family of metalloendopeptidases, which, besides their proteolytic activity, are 
able to act independently from that with other proteins, we were interested to find out, 
whether p42IP4 has the ability to influence the enzymatic activity of NRD. 
4.2 p42IP4 enhances the enzymatic activity of NRD 
 
Here, we could demonstrate that p42IP4 can enhance the enzymatic activity of the 
metalloendopeptidase 3 - 4 times. We measured the cleavage of a peptide derived from the 
bovine adrenal medulla peptide. This cleavage assay was performed in vitro, therefore it still 
has to be elucidated, whether this has functional relevance in vivo. 
Moreover, experiments with NRD lacking the DAC, did not show an enhanced 
enzymatic activity after addition of p42IP4. Therefore, we propose that the binding of p42IP4 to 
the DAC is important for the enzymatic activity of the metalloendopeptidase. We suggest 
that, depending on the part of the metalloendopeptidase where p42IP4 or ligands of NRD are 
bound, the physiological consequences may differ. We propose that the binding of p42IP4 to 
the DAC influences the enzymatic properties of NRD, whereas the binding to other parts of 
the metalloendopeptidase might be important for processes, which do not require the 
enzymatic activity of the metalloendopeptidase. 
The first physiological substrate for NRD was reported recently (Kessler et al., 2011). It 
was demonstrated in that work that NRD is able to complement the proteasome activity, 
whereby it contributes to generation of Cytotoxic T lymphocyte epitopes of an Epstein-Barr 
virus protein. Additionally, NRD is able to enhance the shedding of HB-EGF (Nishi et al., 
2006) and to influence the α-secretase activity of ADAM17 (Hiraoka et al., 2007). Moreover, 
NRD plays a role in the shedding of neuregulin (Ohno et al., 2009), a protein involved in 
myelination.  
NRD was shown to cleave peptides such as somatostatin-28, dynorphin-A (Chesneau et 
al., 1994), α-neoendorphine (Csuhai et al., 1995), and miniglucagon (Fontes et al., 2005) in 
vitro. Recent studies (Bernstein et al., 2007) demonstrated that although NRD can cleave 
somatostatin in vitro, it does not colocalize with somatostatin-28. Nevertheless, besides the 
antigen processing activity of NRD (Kessler et al., 2011) other physiological relevant 
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substrates of NRD are still unknown. Moreover it was discussed that NRD to may have a role 
in neuropeptide metabolism (Seidah and Prat, 2002).  
Whether or not p42IP4 can influence the catalytic activity of NRD in physiological 
environments remains to be elucidated.  
 
4.3  Upregulation of NRD expression after stimulation with RA in SH-SY5Y 
cells not expressing p42IP4 
 
The expression of the proteins p42IP4 and NRD was shown to be regulated during 
development (Aggensteiner and Reiser, 2003) (Fumagalli et al., 1998). In addition to that, we 
could recently demonstrate that the metalloendopeptidase is expressed almost exclusively in 
neurons, with wide, but uneven distribution throughout the human brain (Bernstein et al., 
2007). Moreover, a developmental regulation of the expression of NRD was found, together 
with a concomitant overlap between the expression of p42IP4 and NRD.  
To elucidate the relationship of NRD and p42IP4 during differentiation, we first searched 
for a suitable cell culture model for further investigations. 
Neuroblastoma cells are often used as an experimental model for neuronal 
differentiation and de-differentiation (reviewed in (Edsjo et al., 2007). Application of RA to 
neuroblastoma cells stops their proliferation and causes differentiation into a more neuronal 
cell type (Pahlman et al., 1984). Moreover, the vitamin A metabolite all-trans RA plays an 
important role in early embryonic development, the development of organs and organ 
systems, especially the nervous system. Therefore we decided to stimulate the neuroblastoma 
cell line SH-SY5Y with RA, to analyze changes in the expression of NRD and p42IP4 on both 
mRNA and protein level. 
Although we were able to detect mRNA of both NRD and for p42IP4, our investigations 
to verify the protein expression revealed that p42IP4 was not expressed in these neuroblastoma 
cells. In addition, stimulation with RA did not reveal the expression of the protein p42IP4. 
Therefore, we used this cell line, overexpressing p42IP4 as GFP-fusion protein, as a model to 
elucidate the influence of p42IP4 on NRD expression. 
We demonstrate here that stimulation of untransfected SH-SY5Y cells with 10 µM RA 
results in an upregulation of NRD protein levels, with a 6-fold rise after 15 days. It is known 
from the literature that NRD can be upregulated with RA in SK-N-BE(2) cells, another 
neuroblastoma cell line, albeit after 2 days of RA stimulation (Draoui et al., 1997). Although 
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it was discussed in that publication that NRD might contain RARE elements, which are 
responsible for the upregulation, promoter studies on NRD could not reveal such an element 
(Winter and Pierotti, 2000). For this reason we searched the cisRed (cis-regulatory) database 
(Robertson et al., 2006) for motifs, which could be responsible for the RA-induced 
upregulation of NRD. We found on human chromosome 1 (chr1: 52,117,180-52,117,191) a 
binding site for LXR-alpha_RXR-alpha, which we propose to be the cause for the 
upregulation. As already mentioned above, p42IP4 protein is not expressed in untreated SH-
SY5Y cells and its expression was not induced after RA treatment. The latter finding was not 
surprising, because the search in the data base cisRed (Robertson et al., 2006) revealed neither 
RARE nor RXR elements in the p42IP4 gene.  
The SH-SY5Y cell line was shown to consist of two phenotypes with a majority of 
neuroblast-like cells. Upon stimulation with RA, 25% of the cells grow extensions longer than 
50 µm but at the same time the non-neuronal phenotype increases dramatically (Preis et al., 
1988). Therefore, for all experiments using SH-SY5Y cells treated with 10 µM RA, it was 
necessary to avoid the non-neuronal phenotype, which rapidly overgrows the culture dish 
upon RA stimulation. We selected the neuronal cell type with trypsination. Moreover, it was 
difficult to choose the gene for normalization, because GAPDH and tubulin were upregulated 
in the time-course of the experiments. For actin it was published before that the ratio of actin 
expression relative to the total protein content was significantly increased in SH-SY5Y cells 
differentiated with RA (Asada et al., 1994). Therefore, in our analysis, all genes were 
normalized to the same gene under untreated (day 0) conditions. 
4.4 Influence of p42IP4 on the upregulation of NRD in RA stimulated SH-
SY5Y cells expressing p42IP4 
 
To clarify whether the concomitant expression of NRD and p42IP4 in brain and the 
developmental regulation of both proteins have a physiological role, the influence of p42IP4 on 
the expression of NRD in SH-SY5Y-p42 cells after stimulation with RA was investigated. 
Interestingly, stable transfection of GFP-tagged-p42IP4 into SH-SY5Y cells and 
stimulation with RA for 3, 6, 9, 12, and 15 days shifts the increase in the expression of NRD 
to an earlier time point. NRD appears to be upregulated as early as day 6 in p42IP4-GFP 
transfected SH-SY5Y cells, which represents a shift of 9 days compared to untransfected SH-
SY5Y cells, where NRD is upregulated at day 15. Although the protein expression of NRD is 
decreased in p42IP4 - transfected SH-SY5Y cells at later time points (after day 6) treatment 
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with 10 µM RA, similar results could be obtained with GFP-only transfected SH-SY5Y cells. 
Therefore, the upregulation after day 6 is not the result of overexpression of p42IP4 and most 
likely a result of the expression of the GFP-tag. For this reason, conclusions about the 
expression of NRD and the influence of p42IP4 can be made only until day 6 in GFP-p42IP4 
transfected SH-SY5Y cells.  
Nevertheless, the p42IP4-dependent shift in the upregulation of NRD in SH-SY5Y-
p42IP4 cells after stimulation with RA gives evidence that the developmental colocalization of 
both proteins has functional relevance (Bernstein et al., 2007). We propose that p42IP4 might 
directly influence the transcription of NRD, but further experiments, like chromosome 
immunoprecipitation need to be done to investigate this idea further. 
It is known from the literature that p42IP4 can influence the transcription of certain 
genes. In a study to test the modulators of the activator protein-1 (AP1), using large scale 
genome functional profiling it was shown that p42IP4 is a putative modulator of AP-1 (Chanda 
et al., 2003). p42IP4 highly activates the AP-1 related reporters, the nuclear factor of activated 
T cells response elements (NFAT) and AP-1 (induced with PMA). Moreover, p42IP4 showed a 
lowered activation of the cAMP response element binding protein (CRE). Moreover, the 
transfection of siRNAs, coding for ERK pathway effectors like DGK1, MEKK1 and MEKK2, 
or directed against genes like MAP4K1 related to the JNK-pathway, extinguished the activity 
of p42IP4 on the AP-1 reporter (Chanda et al., 2003).  
We could observe that independently of RA stimulation, cells stably transfected with 
p42IP4-GFP showed a different behavior when treated with trypsin compared to SH-SY5Y-wt 
and GFP-only cells. p42IP4 - transfected cells detached much faster from their substrate 
compared to SH-SY5Y or SH-SY5Y-GFP cells. In this context it is interesting to note that 
p42IP4 can activate the AP-1 promoter (Chanda et al., 2003). This activation is noteworthy 
because p42IP4 can thereby moderate an oncogenic transformation of cells via the AP-1 
signaling pathway, which includes also changes in cell adhesion and stimulates proliferation 
of cells (Chanda et al., 2003). The time course of the upregulation of NRD depends on the cell 
line investigated (15 days in SH-SY5Y cells, as shown here or after 2 or 3 days in SK-N-BE 
cells (Draoui et al., 1997)). It is interesting to note that RA can inhibit the transcription factor 
AP-1 (Schule et al., 1991). p42IP4 can activate the AP-1 pathway and therefore induces 
proliferation. We speculate that by transfection of p42IP4, p42IP4 excerts its influence on the 
focal adhesion proteins (vinculin and paxillin) as published before (Thacker et al., 2004), 
which resulted in earlier detachment of the cells after trypsin treatment. 
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4.5 Influence of tubulin on the localization of NRD and p42IP4 
 
Using confocal microscopy, we found that NRD is localized in the cytosol and in the 
growing neurites of the stimulated SH-SY5Y. Furthermore, after 6 days of RA treatment, 
NRD appears to be localized within vesicular structures, which are even more visible after 9 
days of RA treatment. We conclude that NRD is transported in developing neurites. Staining 
with p42IP4 antibodies showed no expression of this protein, neither in unstimulated nor in 
cells stimulated with RA.  
SH-SY5Y cells, stably transfected with p42IP4-GFP, showed the colocalization of NRD, 
p42IP4 and tubulin in the cytosol and at the plasma membrane. Treatment with nocodazole 
caused a redistribution of p42IP4 and tubulin, but did not change the colocalization of p42IP4 
and tubulin, whereas the colocalization of all three proteins was visible only in vesicular 
structures. We hypothesize that this colocalization, which occurs only in vesicular structures, 
might have also a functional role in transport processes along microtubules. 
The kinesin motor protein KIF13B, which interacts with p42IP4 (Venkateswarlu et al., 
2005), was demonstrated to play a role in Schwann cell myelination, where it contributes to 
the cell membrane homeostasis, through transporting the myotubularin-related protein2 
phospholipid phosphatase to places of myelination (Bolis et al., 2009). 
Interestingly, it was reported that NRD regulates the myelination in the central and 
peripheral nervous system via enhancement of extracellular shedding of neuregulin (NRG1) 
by TACE (Ohno et al., 2009). 
Recent investigations in our laboratory gave evidence that p42IP4 interacts with CNP 
from rat brain mitochondria (Galvita et al., 2009). Moreover, CNP is a microtubule - 
associated protein, which does not only polymerize tubulin but also links tubulin to the cell 
membrane (Bifulco et al., 2002). It was discussed that the localization of p42IP4 in the 
intermembrane space of mitochondria and the interaction with CNP influences the opening of 
the permeability transition pore (PTP) (Galvita et al., 2009). Although p42IP4 thereby 
contributes to drastic changes in the cellular Ca2+ levels, which happen to be disturbed in 
many neurodegenerative diseases (reviewed in (Celsi et al., 2009), the interaction of p42IP4 
with CNP may also have other physiological consequences. 
CNP was discussed to be a transporter for RNA along microtubules, due to its ability 
to bind simultaneously to tubulin and RNA (Gravel et al., 2009). Although the physiological 
role of CNP is unclear, it is thought to play a role in myelination. Interestingly, BACE -/- 
mice also diplay peripheral hypomyelination (Willem et al., 2006), which may be of 
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importance for the role of p42IP4 in neurodegenerative diseases via the interaction with 
RanBPM. 
4.6 Influence of tubulin on the interaction of NRD with p42IP4 
 
Because it was not possible to provide evidence for an interaction of p42IP4 with NRD 
using pulldown experiments, we assumed that the rather weak interaction between both full-
length proteins and possibly depends on other proteins, as most proteins exert their 
physiologic role in the interplay with other proteins.  
Moreover, it was previously reported that NRD colocalizes with β-tubulin (Ma et al., 
2005) and we recently reported an interaction of p42IP4 with α-tubulin (Galvita et al., 2009), 
which makes tubulin an ideal protein partner to support the interaction. 
Nevertheless, one has to be careful when postulating a functional interaction with 
tubulin. Many proteins are known to interact with tubulin and an extensive list of proteins 
which co-sediment with microtubules from rat brain was published before (Sakamoto 2008).  
Being among co-purified proteins does not necessarily mean that those proteins interact 
or maintain a functional relationship. Therefore, we were interested to find out, whether there 
is a simultaneous interaction of both proteins with tubulin. Moreover, we wanted to determine 
whether tubulin might have an impact on the interaction between p42IP4 and NRD and to 
reveal if changes in the tubulin-cytoskeleton affect the interaction of NRD and p42IP4. For 
that, we examined the interaction between full length NRD, p42IP4 and tubulin in SH-SY5Y 
cells and in vitro. 
Using Far Western Blot technique, we show in vitro that the interaction between p42IP4 
and NRD can be enhanced by tubulin. It is critical for these kinds of experiments that the 
protein blotted on the membrane is properly refolded.  
We assume that this must be the case in the experiments performed by us, because 
stereospecific ligands of p42IP4 – D-IP4 and L-IP4, clearly show a different behavior on the 
binding of NRD to p42IP4 on the membrane. We showed here that in Far Western Blots, D-IP4 
diminishes the interaction of NRD and p42IP4, which is similar to previously published results 
(Stricker et al., 2006). Compared to the data published before, the reduction was smaller but 
that difference might be explained by of the different binding capacities for p42IP4 of the DAC 
alone (used in (Stricker et al., 2006) and the full length NRD as used here. 
Interestingly, the enhanced interaction between NRD and p42IP4 could not be observed, 
when tubulin was not polymerized. Polymerized tubulin may increase the probability for the 
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interaction of p42IP4 by bringing p42IP4 and NRD in close proximity. However, the functional 
consequences of an interaction between NRD, p42IP4 and tubulin and more specific the 
differences in the binding properties of NRD, p42IP4 and tubulin, depending on the 
polymerization status of tubulin are not clear.  
Moreover, irrespective of the presence or absence of tubulin, NRD mutants, which have 
a substitution in a catalytic important amino acid residue (C948A), as discussed before in 
(Pierotti et al., 1994) and (Hospital and Prat, 2004) showed no differences in their binding to 
p42IP4. Mutants that lack an entire domain (∆DAC) showed a very small increase of NRD 
binding to p42IP4 in the presence of tubulin.  
Therefore, we conclude that p42IP4 binds not exclusively to the DAC of NRD. 
Moreover, the different binding positions of p42IP4 to NRD might have consequences on the 
regulation by ligands of either NRD or p42IP4. It was previously shown that the interaction of 
p42IP4 with the DAC alone can be regulated by ligands of NRD as well as of p42IP4 (Stricker 
et al. 2006). With the DAC, known to be important for the enzymatic activity of NRD, and 
the place for binding of NRD ligands, one could assume that the regulation by NRD ligands is 
important for processes, where NRD acts as an enzyme. With the here newly found 
interaction of p42IP4 with NRD lacking the DAC, ligands of NRD may not be important for 
the regulation of the binding of p42IP4 outside the DAC of NRD. This may influence 
processes in the cell, which do not require the enzymatic activity of NRD.  
Tubulin does not influence the binding of the NRD-mutant ∆DAC to p42IP4 to the same 
extent like binding to the wild type NRD, which points towards a binding position of tubulin 
to NRD also in the DAC. 
Moreover, while IP4 forces a release of NRD (Stricker et al., 2006) and RanBPM 
(Haase et al., 2008) from p42IP4 the interaction with tubulin might be unaffected by IP4. 
Therefore, the influence of tubulin on the interaction with the p42IP4 ligands requires further 
investigations.  
We speculate that the interaction of NRD, p42IP4, and tubulin might have some 
influence on transport processes, for example via the microtubule plus end directed KIF13B. 
p42IP4 itself interacts directly through its Arf-GAP domain with the stalk domain of the 
kinesin motor protein KIF13B (Venkateswarlu et al., 2005), which was found to be essential 
for the localization of p42IP4 to the leading edges of cells and for the Arf6-GAP activity of 
p42IP4 in vivo. Moreover through the binding of p42IP4 to the fork-head domain (FHA-
domain) of KIF13B, PIP3 vesicles can be connected to the motor protein and can be 
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transported along microtubules to the end of the axon in neuronal cells (Horiguchi et al., 
2006). 
Previous reports suggested that p42IP4 can have dramatic effects on the actin 
cytoskeleton and can bind F-actin directly via its PtdIns(3,4,5)P3-binding pleckstrin homology 
(PH) domain (Thacker et al., 2004). 
Although many proteins are able to bind to either actin or tubulin, very few proteins 
can bind to both actin and tubulin simultaneously. The binding of actin and the modulated 
interaction of p42IP4 with NRD by tubulin may therefore place p42IP4 at such a crosslinker 
position between the actin and tubulin cytoskeleton. Functionally, p42IP4 might serve as an 
anchor between actin and microtubules during the transport of vesicles along microtubules. 
A possible link between the actin- and the tubulin-network was discussed before 
(Halpain and Dehmelt, 2006), and those linker proteins also play a role in growth cone 
development (Dehmelt and Halpain, 2007). Besides their role in growth cone development, 
proteins that act as an actin-tubulin crosslinker are also important in the movement of growth 
cones, in regeneration processes, in wound healing and in virus infection of cells. 
We recently discovered in a yeast-two-hybrid-screen with a human brain cDNA 
library and p42IP4 as bait that several p42IP4-interacting clones represented peptides from the 
microtubule-associated proteins MAP1B and MAP1A (C.B. and G.R., unpublished results). 
Although this was not investigated further, evidence of this interaction in vivo would add to 
the understanding of p42IP4 and interaction with microtubules. 
In this respect, it would be of great interest to know, whether p42IP4 is located in 
growth cones. One could expect p42IP4 to be co-localized with MAP1A/B alongside the axon 
with an interaction or colocalization with NRD. Additionally, it may also depend on the 
localization of p42IP4 in- or outside of mitochondria. As mentioned before, our group 
previously reported that p42IP4 shows mitochondrial localization. In growth cones 
mitochondria are expected to be localized to the central domain and transition zone of the 
growth cone (Geraldo and Gordon-Weeks, 2009). 
Furthermore, investigations to identify the precise tubulin interacting domain of p42IP4 
have to be performed. It is known from the actin-tubulin crosslinker neurofibromin that the 
mutation of the GAP-related domain impairs the binding of neurofibromin to microtubules 
(Xu and Gutmann, 1997) and that tubulin can even inhibit the Ras GAP activity of 
neurofibromin (Bollag et al., 1993). It would be interesting to investigate, whether p42IP4 
displays analogous behavior, because it can bind to both actin and tubulin and work as GAP, 
albeit for Arf5 and Arf6. 
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Assuming that the GAP domain of p42IP4 is responsible for binding to both tubulin and 
NRD and with F-actin binding mostly to the PH2 domain of p42IP4 (Thacker et al., 2004), it 
will be interesting to investigate, whether mutations in the Arf-GAP domain of p42IP4 would 
diminish, if not even abolish the interaction with microtubules‡.  
Interestingly, neurofibromin is an actin tubulin crosslinker, which does not possess a 
tubulin binding domain, similar to MAPs (Li et al., 2001). Furthermore, during the 
development of telencephalic neurons, the expression of neurofibromin is regulated, so that 
depending on the developmental stage, a high coexpression with actin or with tubulin, even 
the colocalization was found to be dependent on the developmental stage (Li et al., 2001). 
In dendritic spines p42IP4 might work as a linker as part of a transport complex, which 
localizes NRD to the postsynaptic membrane for shedding of substrates. Binding of PIP3 or 
PIP2 to p42IP4 may subsequentially fix NRD on the membrane. The binding of the p42IP4 
ligand IP4 to p42IP4 would force the release of NRD from the membrane into the cytosol. 
Additionally, p42IP4 might thereby regulate the shedding of substrates other than the adrenal 
medulla peptide (shown in vitro in this work) by NRD and thereby participate in neuropeptide 
metabolism.  
To verify this hypothesis, it is important to elucidate the precise binding site of p42IP4 
to NRD, but also to clarify the impact of NRD ligands. 
It was published before that the PH2 domain of p42IP4 is the major binding place for 
actin and the PH1 domain has only a minor binding capacity, whereas the Arf-GAP domain is 
not important for the binding of actin (Thacker et al., 2004). Moreover, assuming that the PH2 
domain binds to DAC, the question arises whether binding of p42IP4 ligands would influence 
the binding of p42IP4 to actin and thereby the potential crosslinking function of p42IP4 between 
actin and tubulin.  
 
4.7 Influence of p42IP4 on sAPPα-levels and Aβ-40 production of APP 
Another aim of this study was to investigate, whether p42IP4 has an impact on the 
shedding of the amyloid precursor protein (APP). 
It is known that p42IP4 is localized in plaques of AD-patients, but the role of this protein 
in AD is still unknown (Reiser and Bernstein, 2002). 
It was proposed before (Skovronsky et al., 2001) that the processing of APP is balanced 
between either amyloidogenic pathway, via BACE1 or non-amyloidogenic via α-secretases 
                                                 
‡
 Unpublished preliminary experiments with p42IP4 and a mutation in the Arf-GAP domain support this idea. 
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(TACE for example). A shift towards APP processing via BACE results in increased levels of 
Aß, whereas preferential cleavage by α-secretases leads to the release of the neuroprotective 
sAPPα. A shift towards the amyloidogenic pathway may happen through inhibition of α-
secretases or increased activation of BACE. 
Several interaction partners of p42IP4 were shown to be involved in processes connected 
to AD, albeit mostly not in a direct way. The PKC can activate directly (Diaz-Rodriguez et 
al., 2002) or indirectly the α-secretase, nucleolin is able to regulate the mRNA of APP (Zaidi 
and Malter, 1995) and RanBPM promotes the BACE1 induced cleavage of APP (Lakshmana 
et al., 2009). 
For NRD it was previously reported that it can enhance the TNF-α-converting enzyme 
(TACE) – induced α-cleavage of APP which in turn leads to reduced production of the 
neurotoxic Aß (Hiraoka et al., 2007). Moreover, knockdown of the NRD protein expression 
leads to decreased α-secretase-activity and increased production of Aß. 
Although p42IP4 interacts with NRD and other proteins favoring the non-amyloidogenic 
pathway, it was found to be co-localized with Aß-plaques in AD-brains (Reiser and Bernstein, 
2002). Moreover, RanBPM, another interaction partner of the neuronal protein p42IP4 (Haase 
et al., 2008), was found to interact with BACE1 and to increase the release of Aß (Lakshmana 
et al., 2009). 
Together with the enhancement of TACE – induced α-cleavage of APP via NRD 
(Hiraoka et al., 2007) and the decreased α-secretase-activity after knock-down of the NRD 
protein, sets p42IP4 at an interesting position within the network of proteins involved in APP 
shedding. Our hypothesis was that p42IP4 might have either a neuroprotective role via 
interaction with NRD, resulting in an increase of sAPPα release or a neurotoxic role via 
RanBPM and increased production of Aß. We firstly focused on the anti-amyloidogenic 
pathway, because our data on the influence of p42IP4 on the expression of NRD let us expect 
an increase of sAPPα release via NRD and TACE. We investigated the sAPPα-secretion, via 
Western blot analysis. Although the overexpression of p42IP4 in SH-SY5Y cells can influence 
the time-dependent upregulation of NRD after stimulation with 10 µM RA, this 
overexpression together with a concomitant treatment with RA has no clear effect on the 
shedding of APP via α-secretases. The reasons for the inconsistent detection of sAPPα are not 
obvious. 
It might be that the sAPPα release was not influenced by p42IP4, because the 
catalytically activity of NRD is not necessary for enhanced sAPPα production (Hiraoka et al., 
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2007). The modulation of the enzymatic activity of NRD by p42IP4 may therefore have a 
different physiological function, which is not related to APP-shedding. 
We can exclude that the inconsistent detectable levels of sAPPα are a result of technical 
problems with the antibody used for the experiments (6E10). We confirmed the functionality 
of this antibody with recombinant sAPPα (not shown).  
Because of the difficulties in consistent sAPPα detection, we instead suspected that the 
influences of p42IP4 alone might shift the processing of APP towards the amyloidogenic 
pathway but are imbalanced through the effect of upregulation of NRD. We therefore avoided 
stimulation with RA for the experiments aiming to detect the release of Aβ40. An ELISA to 
detect the Aβ40-release revealed that the levels of this peptide remain at a basal level, even 
under serum-free condition of the cells for one week. 
However, it is still a miracle, how p42IP4 ends up in the amyloid plaques of AD-brains. 
Although p42IP4 does not directly influence the α-secretase pathway via interaction with 
NRD, it also does not directly affect the β-secretase pathway. Most recent papers propose that 
the equilibrium between α-secretases and BACE1 might not be the critical point for 
developing AD, as it was assumed before (Jang et al., 2010). They discuss that the non-
amyloidogenic p3 peptides, produced after α- secretase and γ-secretase cleavage, can form ion 
channels, which can permit Ca2+-influx. The resulting high Ca2+ concentration is then the 
cause for disruption of neurites and finally leads to the death of neurons. It is possible that the 
localization of p42IP4 in mitochondria and the influence on the opening of the permeability 
transition pore contributes more to the localization of p42IP4 in plaques of AD-brains than its 
interaction with RanBPM or NRD. 
 
In summary, although the physiological role of the interaction between p42IP4 and 
NRD is not yet clear, we propose that depending on the spatial and temporal localization of 
both proteins the interaction will translate into different physiological functions.  
During development, p42IP4 may influence the protein expression of NRD and thereby 
allowing NRD to exert its enzymatic or non-enzymatic functions at an earlier time.  
Additionally, our results may place p42IP4 at a linker position between the actin and 
the tubulin network. Through interaction of p42IP4 with adapter proteins of vesicles like 
KIF13B, p42IP4 may influence transport processes along microtubules, which also play a role 
in growth cone development.  
In neurodegenerative diseases, p42IP4, although found in amyloid plaques of AD 
brains, is not directly involved in the shedding of APP. p42IP4 instead may also participate in 
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neurodegenerative diseases linked to disturbances of myelination via an interplay with NRD 
and between NRD, BACE1, NRG1 and its interaction partners. Besides the putative role of 
p42IP4 in neurodegenerative diseases, p42IP4 may participate in neuropeptide metabolism, as it 
was shown in this work that p42IP4 is not a substrate for NRD but can modulate the cleavage 
of a neuropeptide-derived substrate of NRD.  
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5 Abstract  
The study presented here focused on the characterization of the interaction of the neuronal 
protein p42IP4 (centaurin α1; ADAP1) with the metalloendopeptidase nardilysin (NRD) and the 
modification of the interaction through tubulin. 
NRD belongs to the inverzincin / M16 family of metalloendopeptidases, which have the 
ability to act as a protease and in a non-enzymatic way. We investigated, whether NRD acts as 
protease on p42IP4. We could show here that recombinant, enzymatically active NRD does not cleave 
p42IP4. Using a substrate of the metalloendopeptidase in an enzymatic assay revealed that the presence 
of p42IP4 enhances the enzymatic activity of NRD.  
It has been published before that p42IP4 and NRD are developmentally regulated with a time-
dependent overlap in their expression in developing human brain. To investigate this on cellular level, 
we used SH-SY5Y cells and differentiated them into a more neuronal phenotype with 10 µM retinoic 
acid (RA). Differentiation of these neuroblastoma cells by RA treatment resulted in an upregulation of 
NRD protein levels, with a 6-fold rise after 15 days. NRD expression was detectable in the neurites of 
RA-stimulated SH-SY5Y cells and NRD was localized in vesicular structures.  
p42IP4 is not expressed in SH-SY5Y cells and an expression cannot be induced through 
stimulation with RA. We therefore produced SH-SY5Y cells, stably transfected with GFP-tagged-
p42IP4 and used this cell system as a model to investigate whether a functional interaction exists 
between both proteins. Interestingly SH-SY5Y-p42IP4 cells showed an enhanced NRD protein 
expression already at an earlier time point after RA treatment. We propose that p42IP4 influences the 
transcription of NRD. 
It is known from the literature that NRD can interact with β-tubulin and p42IP4 with α-tubulin. 
Therefore, we were interested to find out, whether tubulin can influence the interaction between NRD 
and p42IP4. Using confocal microscopy, we observed a colocalization of NRD, p42IP4, and tubulin in 
the cytosol and on the plasma membrane in the neuroblastoma cells SH-SY5Y, stably transfected with 
p42IP4. To examine the importance of tubulin for the interaction of NRD with p42IP4 we treated these 
cells with nocodazole, a microtubule depolymerisation agent. Nocodazole did not affect colocalization 
of p42IP4 and tubulin, but caused a clear redistribution of the proteins in cells. A colocalization of 
p42IP4, tubulin, and NRD was visible exclusively in multiple foci. We hypothesize that this 
colocalization, which occurs only in these foci, might have a functional role in transport processes 
along microtubules, via an interaction with other proteins. p42IP4 might help to transport NRD along 
microtubules via an interaction with KIF13B. To investigate the interaction between NRD, p42IP4, and 
tubulin observed in the neuroblastoma cells, we performed Far-Western Blots to detect the protein-
protein interactions directly. We could demonstrate that tubulin potentiates the interaction between 
NRD and functionally renatured p42IP4. The enhancement depends on the polymerization of tubulin. 
Moreover, the interaction between p42IP4, NRD, and tubulin is very specific. We tested several 
mutants of NRD for their binding properties to tubulin and p42IP4. NRD, with a mutation in the Zn2+-
binding motif (HFLAH->HFLEH) behaved like unmutated NRD. The mutation of a highly conserved 
cysteine residue in NRD to alanine abolished the potentiation by tubulin. The NRD mutant lacking the 
characteristic acidic domain (DAC) was able to bind p42IP4, but addition of tubulin could not 
significantly potentiate the binding to p42IP4. The interaction of p42IP4 with ∆DAC proves that p42IP4 
also binds to NRD outside the DAC. The tubulin mediated enhancement of the interaction between 
p42IP4 and NRD, supports our concept of a novel role of p42IP4 as a linker between the actin and 
tubulin network in neural cells.  
Furthermore, the interaction of both proteins is possibly important with regard to Alzheimer’s 
disease (AD). The protein p42IP4 has been found to be colocalized with neuritic plaques in AD brains 
and to interact with RanBPM- a protein, which can activate the β-secretase (BACE1). Opposite to that, 
NRD has been shown to enhance the release of the neuroprotective sAPPα. We therefore studied 
whether p42IP4 affects the cleavage of APP. We could demonstrate here that overexpression of p42IP4 
in SH-SY5Y cells has no effect on the shedding of APP, as both the release of the neuroprotective 
sAPPα and the release of Aβ40 remain on the basal level. 
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6 Zusammenfassung  
In der hier präsentierten Arbeit wurde die Interaktion zwischen dem neuronalen Protein p42IP4 
(centaurin α1; ADAP1) und der Metalloendopeptidase Nardilysin (NRD), sowie die Modifikation 
dieser Interaktion durch Tubulin untersucht. 
NRD gehört zur Familie der Inverzinkin / M16 Metalloendopeptidasen. Einige Mitglieder 
dieser Familie haben die Fähigkeit, sowohl als Protease, wie auch auf nicht-enzymatische Weise ihre 
Wirkung zu entfalten. Es wurde hier als erstes untersucht, ob NRD als Protease auf p42IP4 wirken 
kann. Es konnte dabei gezeigt werden, dass rekombinantes, enzymatisch aktives NRD p42IP4 nicht 
schneidet. Durch den Einsatz eines Substrates der Metalloendopeptidase in einem enzymatischen 
Assay konnte gezeigt werden, dass unter Anwesenheit von p42IP4 die enzymatische Aktivität von NRD 
verstärkt wird. 
Es ist aus Veröffentlichungen bekannt, dass p42IP4 und NRD entwicklungsbiologisch reguliert 
werden und die Expression beider Proteine während der Entwicklung des humanen Gehirns eine 
zeitliche Überlappung aufweist. Um dies auf zellulärer Ebene zu untersuchen, verwendeten wir hier 
die Neuroblastoma Zellen SH-SY5Y, um diese mit Hilfe von 10 µM Retinsäure (RA) in einen 
neuronaleren Phänotyp zu differenzieren. Die Differenzierung dieser Neuroblastomazellen mit Hilfe 
von RA hatte eine verstärkte Expression von NRD zur Folge, wobei nach 15 Tagen ein 6-facher 
Anstieg der NRD-Expression zu verzeichnen war. Die Expression von NRD ließ sich dabei in den 
Neuriten der mit RA stimulierten SH-SY5Y Zellen nachweisen und NRD konnte auch in vesikulären 
Strukturen beobachtet werden.  
p42IP4 hingegen wird nicht in SH-SY5Y Zellen exprimiert und die Expression kann auch nicht 
durch Stimulation mit RA induziert werden. Deshalb wurden SH-SY5Y-p42IP4 Zellen hergestellt und 
als Modell genutzt, um zu untersuchen, inwiefern eine funktionelle Interaktion zwischen beiden 
Proteinen besteht. Interessanterweise zeigten SH-SY5Y Zellen, die stabil mit GFP-p42IP4 transfiziert 
wurden, zu früheren Zeitpunkten der RA Behandlung eine verstärkte Expression von NRD. Es wird 
deshalb vorgeschlagen, dass p42IP4 die Transkription von NRD beeinflusst. 
Es ist aus der Literatur bekannt, dass NRD mit β-Tubulin und p42IP4 mit α-Tubulin interagiert. 
Aus diesem Grund wollten wir herauszufinden, ob Tubulin die Interaktion zwischen NRD und p42IP4 
beeinflussen kann. Mittels Konfokalmikroskopie konnte in SH-SY5Y Neuroblastomazellen, die stabil 
mit p42IP4 transfiziert wurden, eine Kolokalisation von NRD, p42IP4 und Tubulin im Zytosol und an 
der Plasmamembran vorgefunden werden. Um die Bedeutung von Tubulin für die Interaktion von 
NRD mit p42IP4 genauer zu untersuchen, wurden diese Zellen mit Nocodazol behandelt, welches eine 
Substanz darstellt, die Mikrotubuli depolymerisieren kann. Nocodazol zeigte keine Beeinflussung der 
Kolokalisation von p42IP4 und Tubulin, verursachte aber eine eindeutige Umverteilung dieser Proteine 
in den Zellen, wobei eine Kolokalisation von p42IP4, Tubulin und NRD ausschließlich in Multiplen 
Foci zu verzeichnen war. Wir vermuten, dass diese Kolokalisation im Zusammenspiel mit anderen 
Zusammenfassung 
 92 
Proteinen eine Rolle beim Transport entlang von Mikrotubuli spielen könnte. p42IP4 könnte dabei via 
Interaktion mit KIF13B, eine Rolle beim Transport von NRD entlang der Mikrotubuli besitzen. Um 
die in den Neuroblastomazellen beobachtete Interaktion zwischen NRD, p42IP4 und Tubulin zu 
untersuchen, wurden Far Western Blots durchgeführt. Die Protein-Protein Interaktion wurde dabei 
direkt auf dem Western Blot detektiert. Es konnte gezeigt werden, dass Tubulin die Interaktion 
zwischen NRD und dem zuvor auf der Membran funktionell renaturierten p42IP4 verstärkt. Jedoch 
scheint diese Verstärkung vom Polymerisationsstatus des Tubulins abzuhängen. 
Weiterhin scheint die Interaktion zwischen p42IP4, NRD und Tubulin sehr spezifisch zu sein. 
Wir untersuchten verschiedene Mutanten von NRD hinsichtlich ihrer Bindungseigenschaften 
gegenüber Tubulin und p42IP4. Die NRD-Mutante, die eine Mutation im Zn2+-bindenden Motiv 
(HFLAH->HFLEH) besitzt, verhielt sich dabei wie nicht mutiertes NRD. Interessanterweise 
verursachte die Mutation eines in NRD hoch konservierten Cysteins zu Alanin eine Aufhebung der 
Potenzierung durch Tubulin. Die NRD-Mutante, der die charakteristische Saure Domäne (DAC) fehlt, 
war in der Lage p42IP4 zu binden, aber die Zugabe von Tubulin konnte die Interaktion mit p42IP4 nicht 
signifikant potenzieren. Die Interaktion von p42IP4 mit der Deletionsmutante ∆DAC zeigt, dass p42IP4 
bei der Interaktion mit NRD auch außerhalb der DAC binden kann. Durch die von Tubulin vermittelte 
Verstärkung der Interaktion zwischen p42IP4 und NRD schlagen wir für p42IP4 eine neue Rolle als 
Linker zwischen dem Actin- und Tubulin-Zytoskelett in neuronalen Zellen vor. 
Darüber hinaus ist die Interaktion beider Proteine möglicherweise im Hinblick auf die 
Alzheimer Erkrankung (AD) von Bedeutung. Das Protein p42IP4 wurde in Gehirnen von AD Patienten 
vorgefunden, wobei es mit den AD-Plaques kolokalisiert. Weiterhin interagiert p42IP4 mit RanBPM, 
einem Protein das die β-Sekretase (BACE1) aktivieren kann. Im Gegensatz dazu ist von NRD bekannt, 
dass es die Freisetzung des neuroprotektiven sAPPα verstärkt. Deshalb wurde untersucht, ob p42IP4 
einen Effekt auf die Spaltung von APP hat. Es konnte gezeigt werden, dass die Überexprimierung von 
p42IP4 in SH-SY5Y Zellen keinen Einfluß auf die Prozessierung von APP hat. Sowohl die Freisetzung 
von neuroprotektivem sAPPα, wie auch die Freisetzung von Aβ40 bleiben auf einem basalen Spiegel. 
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8 Abbreviations 
aa    amino acids 
AD    Alzheimer’s disease 
ADAP1   Arf-GAP with dual PH domain-containing protein 1 
Aβ    amyloid ß-peptide 
ADAM10   A disintegrin And Metalloproteinase 10 
ADAM17   A Disintegrin And Metalloproteinase 17 
APP    amyloid precursor protein 
AP-1    activator protein 1 
Arf    ADP-ribosylation factor 
Arf-GAP   ADP-ribosylation factor- GTPase-Activating Protein 
BACE    β-secretase 
bp    base pairs 
BSA    bovine serum albumin 
C-terminal   carboxyl terminal 
CNP    2', 3’-Cyclic-nucleotide 3'-phosphodiesterase 
CNS    central nervous system 
 
DMEM   Dulbecco’s Modified Eagle’s Medium 
DMSO   dimethylsulfoxide 
DNA    desoxyribonucleic acid 
DNase     desoxyribonuclease 
dNTPs    desoxyribonucleotides 
DTT    dithiothreitol 
DAC    Acidic Domain 
ECL    enhanced chemiluminescence 
EDTA     ethylene-diamine-tetra-acetic acid 
EGF    Epidermal growth factor 
ELISA   enzyme-linked immunosorbent assay 
ERK    extracellular-signal-regulated kinase 
EtOH    ethanol 
EtBr    ethidium bromide 
FCS    fetal calf serum 
FSBB    fetal calf serum blocking buffer 
 
GAP    GTPase-Activating Protein 
GAPDH   glycerinaldehyde-3-phosphate-dehydrogenase 
GEF    Guanine nucleotide exchange factor 
GFP     green fluorescent protein 
GPCR     G protein-coupled receptor 
GSH    glutathione sepharose 
GST    glutathione S-transferase 
GTP    Guanosine-5'-triphosphate 
HBSS    Hank’s Buffered Salt Solution 
HB-EGF   Heparin-binding EGF-like growth factor 
HEK293   Human Embryonic Kidney 293 cells 
HRP    Horseradish peroxidase 
hsNRD1   homo sapiens NRD1 
IPTG    Isopropylthio-β-galactoside 
IP4    Inositol-tetrakis-phosphate 
 
kDa    kilo Dalton 
MATra   Magnet Assisted Transfection 
MAP    microtubule associated protein  
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MAP kinase   Mitogen-activated protein kinase 
MPP    mitochondrial processing peptidase 
N-terminal   amino-terminal 
NF1    neurofibromin 1 
NRG1     neuregulin 1 
 
OD    optical density 
ON    overnight 
PAGE     polyacrylamide gel electrophoresis 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
PER    ammonium peroxydisulfate 
PFA    paraformaldehyde solution 
PH    pleckstrin homology 
PI3K    Phosphatidylinositol 3-kinase 
PIP3    Phosphatidylinositol (3,4,5)-trisphosphate 
PIP2    Phosphatidylinositol (3,4)-bisphosphate 
PKC    protein kinase C 
PS1    presenilin 1 
PTP    permeability transition pore 
 
RNA    ribonucleic acid 
RNase     ribonuclease 
RA    all-trans Retinoic Acid 
RAR    retinoic acid nuclear receptors 
RXR    retinoid X receptor 
RARE     RA-responsive elements 
RT    room temperature 
RT-PCR   reverse transcriptase-polymerase chain reaction; 
Sf9    Spodoptera frugiperda 
SDS    sodium dodecylsulfate 
siRNA     small interfering RNA 
TACE     TNF-α-converting enzyme 
TCA    Trichloroacetic acid; 
TEMED   tetramethylethylenediamine 
TNF-α    Tumor necrosis factor-α 
wt    wild type 
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